Strengthening of CYFRA 21-1 using urine creatinine correction as potential endometriosis biomarker 

Strengthening of CYFRA 21-1 using urine... | F1000Research "use strict";function _typeof(t){return(_typeof="function"==typeof Symbol&&"symbol"==typeof Symbol.iterator?function(t){return typeof t}:function(t){return t&&"function"==typeof Symbol&&t.constructor===Symbol&&t!==Symbol.prototype?"symbol":typeof t})(t)}!function(){var t=function(){var t,e,o=[],n=window,r=n;for(;r;){try{if(r.frames.__tcfapiLocator){t=r;break}}catch(t){}if(r===n.top)break;r=r.parent}t||(!function t(){var e=n.document,o=!!n.frames.__tcfapiLocator;if(!o)if(e.body){var r=e.createElement("iframe");r.style.cssText="display:none",r.name="__tcfapiLocator",e.body.appendChild(r)}else setTimeout(t,5);return!o}(),n.__tcfapi=function(){for(var t=arguments.length,n=new Array(t),r=0;r 3&&2===parseInt(n[1],10)&&"boolean"==typeof n[3]&&(e=n[3],"function"==typeof n[2]&&n[2]("set",!0)):"ping"===n[0]?"function"==typeof n[2]&&n[2]({gdprApplies:e,cmpLoaded:!1,cmpStatus:"stub"}):o.push(n)},n.addEventListener("message",(function(t){var e="string"==typeof t.data,o={};if(e)try{o=JSON.parse(t.data)}catch(t){}else o=t.data;var n="object"===_typeof(o)&&null!==o?o.__tcfapiCall:null;n&&window.__tcfapi(n.command,n.version,(function(o,r){var a={__tcfapiReturn:{returnValue:o,success:r,callId:n.callId}};t&&t.source&&t.source.postMessage&&t.source.postMessage(e?JSON.stringify(a):a,"*")}),n.parameter)}),!1))};"undefined"!=typeof module?module.exports=t:t()}(); dataLayer = dataLayer || []; // Standard GTM initialization - Google Consent Mode handles consent automatically (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+ '>m_auth=hzk0Vc3qFsQYhCrIoHz68A>m_preview=env-1>m_cookies_win=x';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-MWFK8L5J'); ;window.NREUM||(NREUM={});NREUM.init={distributed_tracing:{enabled:true},privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]}}; ;NREUM.loader_config={accountID:"438030",trustKey:"438030",agentID:"772317073",licenseKey:"97f8f67f26",applicationID:"772317073"} ;NREUM.info={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",licenseKey:"97f8f67f26",applicationID:"772317073",sa:1} ;/*! For license information please see nr-loader-spa-1.236.0.min.js.LICENSE.txt */ (()=>{"use strict";var e,t,r={5763:(e,t,r)=>{r.d(t,{P_:()=>l,Mt:()=>g,C5:()=>s,DL:()=>v,OP:()=>T,lF:()=>D,Yu:()=>y,Dg:()=>h,CX:()=>c,GE:()=>b,sU:()=>_});var n=r(8632),i=r(9567);const o={beacon:n.ce.beacon,errorBeacon:n.ce.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0},a={};function s(e){if(!e)throw new Error("All info objects require an agent identifier!");if(!a[e])throw new Error("Info for ".concat(e," was never set"));return a[e]}function c(e,t){if(!e)throw new Error("All info objects require an agent identifier!");a[e]=(0,i.D)(t,o),(0,n.Qy)(e,a[e],"info")}var u=r(7056);const d=()=>{const e={blockSelector:"[data-nr-block]",maskInputOptions:{password:!0}};return{allow_bfcache:!0,privacy:{cookies_enabled:!0},ajax:{deny_list:void 0,enabled:!0,harvestTimeSeconds:10},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},session:{domain:void 0,expiresMs:u.oD,inactiveMs:u.Hb},ssl:void 0,obfuscate:void 0,jserrors:{enabled:!0,harvestTimeSeconds:10},metrics:{enabled:!0},page_action:{enabled:!0,harvestTimeSeconds:30},page_view_event:{enabled:!0},page_view_timing:{enabled:!0,harvestTimeSeconds:30,long_task:!1},session_trace:{enabled:!0,harvestTimeSeconds:10},harvest:{tooManyRequestsDelay:60},session_replay:{enabled:!1,harvestTimeSeconds:60,sampleRate:.1,errorSampleRate:.1,maskTextSelector:"*",maskAllInputs:!0,get blockClass(){return"nr-block"},get ignoreClass(){return"nr-ignore"},get maskTextClass(){return"nr-mask"},get blockSelector(){return e.blockSelector},set blockSelector(t){e.blockSelector+=",".concat(t)},get maskInputOptions(){return e.maskInputOptions},set maskInputOptions(t){e.maskInputOptions={...t,password:!0}}},spa:{enabled:!0,harvestTimeSeconds:10}}},f={};function l(e){if(!e)throw new Error("All configuration objects require an agent identifier!");if(!f[e])throw new Error("Configuration for ".concat(e," was never set"));return f[e]}function h(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");f[e]=(0,i.D)(t,d()),(0,n.Qy)(e,f[e],"config")}function g(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");var r=l(e);if(r){for(var n=t.split("."),i=0;i {r.d(t,{D:()=>i});var n=r(50);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.Z)("Setting a Configurable requires an object as input");if(!t||"object"!=typeof t)return(0,n.Z)("Setting a Configurable requires a model to set its initial properties");const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let a in o)if(void 0!==e[a])try{"object"==typeof e[a]&&"object"==typeof t[a]?r[a]=i(e[a],t[a]):r[a]=e[a]}catch(e){(0,n.Z)("An error occurred while setting a property of a Configurable",e)}return r}catch(e){(0,n.Z)("An error occured while setting a Configurable",e)}}},6818:(e,t,r)=>{r.d(t,{Re:()=>i,gF:()=>o,q4:()=>n});const n="1.236.0",i="PROD",o="CDN"},385:(e,t,r)=>{r.d(t,{FN:()=>a,IF:()=>u,Nk:()=>f,Tt:()=>s,_A:()=>o,il:()=>n,pL:()=>c,v6:()=>i,w1:()=>d});const n="undefined"!=typeof window&&!!window.document,i="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),o=n?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),a=""+o?.location,s=/iPad|iPhone|iPod/.test(navigator.userAgent),c=s&&"undefined"==typeof SharedWorker,u=(()=>{const e=navigator.userAgent.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),d=Boolean(n&&window.document.documentMode),f=!!navigator.sendBeacon},1117:(e,t,r)=>{r.d(t,{w:()=>o});var n=r(50);const i={agentIdentifier:"",ee:void 0};class o{constructor(e){try{if("object"!=typeof e)return(0,n.Z)("shared context requires an object as input");this.sharedContext={},Object.assign(this.sharedContext,i),Object.entries(e).forEach((e=>{let[t,r]=e;Object.keys(i).includes(t)&&(this.sharedContext[t]=r)}))}catch(e){(0,n.Z)("An error occured while setting SharedContext",e)}}}},8e3:(e,t,r)=>{r.d(t,{L:()=>d,R:()=>c});var n=r(2177),i=r(1284),o=r(4322),a=r(3325);const s={};function c(e,t){const r={staged:!1,priority:a.p[t]||0};u(e),s[e].get(t)||s[e].set(t,r)}function u(e){e&&(s[e]||(s[e]=new Map))}function d(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:"",t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:"feature";if(u(e),!e||!s[e].get(t))return a(t);s[e].get(t).staged=!0;const r=[...s[e]];function a(t){const r=e?n.ee.get(e):n.ee,a=o.X.handlers;if(r.backlog&&a){var s=r.backlog[t],c=a[t];if(c){for(var u=0;s&&u {let[t,r]=e;return r.staged}))&&(r.sort(((e,t)=>e[1].priority-t[1].priority)),r.forEach((e=>{let[t]=e;a(t)})))}function f(e,t){var r=e[1];(0,i.D)(t[r],(function(t,r){var n=e[0];if(r[0]===n){var i=r[1],o=e[3],a=e[2];i.apply(o,a)}}))}},2177:(e,t,r)=>{r.d(t,{c:()=>f,ee:()=>u});var n=r(8632),i=r(2210),o=r(1284),a=r(5763),s="nr@context";let c=(0,n.fP)();var u;function d(){}function f(e){return(0,i.X)(e,s,l)}function l(){return new d}function h(){u.aborted=!0,u.backlog={}}c.ee?u=c.ee:(u=function e(t,r){var n={},c={},f={},g=!1;try{g=16===r.length&&(0,a.OP)(r).isolatedBacklog}catch(e){}var p={on:b,addEventListener:b,removeEventListener:y,emit:v,get:x,listeners:w,context:m,buffer:A,abort:h,aborted:!1,isBuffering:E,debugId:r,backlog:g?{}:t&&"object"==typeof t.backlog?t.backlog:{}};return p;function m(e){return e&&e instanceof d?e:e?(0,i.X)(e,s,l):l()}function v(e,r,n,i,o){if(!1!==o&&(o=!0),!u.aborted||i){t&&o&&t.emit(e,r,n);for(var a=m(n),s=w(e),d=s.length,f=0;fn,p:()=>i});var n=r(2177).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}},4322:(e,t,r)=>{r.d(t,{X:()=>o});var n=r(5546);o.on=a;var i=o.handlers={};function o(e,t,r,o){a(o||n.E,i,e,t,r)}function a(e,t,r,i,o){o||(o="feature"),e||(e=n.E);var a=t[o]=t[o]||{};(a[r]=a[r]||[]).push([e,i])}},3239:(e,t,r)=>{r.d(t,{bP:()=>s,iz:()=>c,m$:()=>a});var n=r(385);let i=!1,o=!1;try{const e={get passive(){return i=!0,!1},get signal(){return o=!0,!1}};n._A.addEventListener("test",null,e),n._A.removeEventListener("test",null,e)}catch(e){}function a(e,t){return i||o?{capture:!!e,passive:i,signal:t}:!!e}function s(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;window.addEventListener(e,t,a(r,n))}function c(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;document.addEventListener(e,t,a(r,n))}},4402:(e,t,r)=>{r.d(t,{Ht:()=>u,M:()=>c,Rl:()=>a,ky:()=>s});var n=r(385);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function a(){const e=n._A?.crypto||n._A?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(31))),i.split("").map((e=>"x"===e?o(t,++r).toString(16):"y"===e?(3&o()|8).toString(16):e)).join("")}function s(e){const t=n._A?.crypto||n._A?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(31)));const a=[];for(var s=0;s {r.d(t,{Bq:()=>n,Hb:()=>o,oD:()=>i});const n="NRBA",i=144e5,o=18e5},7894:(e,t,r)=>{function n(){return Math.round(performance.now())}r.d(t,{z:()=>n})},7243:(e,t,r)=>{r.d(t,{e:()=>o});var n=r(385),i={};function o(e){if(e in i)return i[e];if(0===(e||"").indexOf("data:"))return{protocol:"data"};let t;var r=n._A?.location,o={};if(n.il)t=document.createElement("a"),t.href=e;else try{t=new URL(e,r.href)}catch(e){return o}o.port=t.port;var a=t.href.split("://");!o.port&&a[1]&&(o.port=a[1].split("/")[0].split("@").pop().split(":")[1]),o.port&&"0"!==o.port||(o.port="https"===a[0]?"443":"80"),o.hostname=t.hostname||r.hostname,o.pathname=t.pathname,o.protocol=a[0],"/"!==o.pathname.charAt(0)&&(o.pathname="/"+o.pathname);var s=!t.protocol||":"===t.protocol||t.protocol===r.protocol,c=t.hostname===r.hostname&&t.port===r.port;return o.sameOrigin=s&&(!t.hostname||c),"/"===o.pathname&&(i[e]=o),o}},50:(e,t,r)=>{function n(e,t){"function"==typeof console.warn&&(console.warn("New Relic: ".concat(e)),t&&console.warn(t))}r.d(t,{Z:()=>n})},2587:(e,t,r)=>{r.d(t,{N:()=>c,T:()=>u});var n=r(2177),i=r(5546),o=r(8e3),a=r(3325);const s={stn:[a.D.sessionTrace],err:[a.D.jserrors,a.D.metrics],ins:[a.D.pageAction],spa:[a.D.spa],sr:[a.D.sessionReplay,a.D.sessionTrace]};function c(e,t){const r=n.ee.get(t);e&&"object"==typeof e&&(Object.entries(e).forEach((e=>{let[t,n]=e;void 0===u[t]&&(s[t]?s[t].forEach((e=>{n?(0,i.p)("feat-"+t,[],void 0,e,r):(0,i.p)("block-"+t,[],void 0,e,r),(0,i.p)("rumresp-"+t,[Boolean(n)],void 0,e,r)})):n&&(0,i.p)("feat-"+t,[],void 0,void 0,r),u[t]=Boolean(n))})),Object.keys(s).forEach((e=>{void 0===u[e]&&(s[e]?.forEach((t=>(0,i.p)("rumresp-"+e,[!1],void 0,t,r))),u[e]=!1)})),(0,o.L)(t,a.D.pageViewEvent))}const u={}},2210:(e,t,r)=>{r.d(t,{X:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},1284:(e,t,r)=>{r.d(t,{D:()=>n});const n=(e,t)=>Object.entries(e||{}).map((e=>{let[r,n]=e;return t(r,n)}))},4351:(e,t,r)=>{r.d(t,{P:()=>o});var n=r(2177);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}}}},3960:(e,t,r)=>{r.d(t,{K:()=>a,b:()=>o});var n=r(3239);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.bP)("load",e,t)}function a(e){if(i())return e();(0,n.iz)("DOMContentLoaded",e)}},8632:(e,t,r)=>{r.d(t,{EZ:()=>u,Qy:()=>c,ce:()=>o,fP:()=>a,gG:()=>d,mF:()=>s});var n=r(7894),i=r(385);const o={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return i._A.NREUM||(i._A.NREUM={}),void 0===i._A.newrelic&&(i._A.newrelic=i._A.NREUM),i._A.NREUM}function s(){let e=a();return e.o||(e.o={ST:i._A.setTimeout,SI:i._A.setImmediate,CT:i._A.clearTimeout,XHR:i._A.XMLHttpRequest,REQ:i._A.Request,EV:i._A.Event,PR:i._A.Promise,MO:i._A.MutationObserver,FETCH:i._A.fetch}),e}function c(e,t,r){let i=a();const o=i.initializedAgents||{},s=o[e]||{};return Object.keys(s).length||(s.initializedAt={ms:(0,n.z)(),date:new Date}),i.initializedAgents={...o,[e]:{...s,[r]:t}},i}function u(e,t){a()[e]=t}function d(){return function(){let e=a();const t=e.info||{};e.info={beacon:o.beacon,errorBeacon:o.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),s(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},7956:(e,t,r)=>{r.d(t,{N:()=>i});var n=r(3239);function i(e){let t=arguments.length>1&&void 0!==arguments[1]&&arguments[1],r=arguments.length>2?arguments[2]:void 0,i=arguments.length>3?arguments[3]:void 0;return void(0,n.iz)("visibilitychange",(function(){if(t)return void("hidden"==document.visibilityState&&e());e(document.visibilityState)}),r,i)}},1214:(e,t,r)=>{r.d(t,{em:()=>v,u5:()=>N,QU:()=>S,_L:()=>I,Gm:()=>L,Lg:()=>M,gy:()=>U,BV:()=>Q,Kf:()=>ee});var n=r(2177);const i="nr@original";var o=Object.prototype.hasOwnProperty,a=!1;function s(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");var a,s,c,u="-"===n.charAt(0);for(c=0;c 2?n-2:0),o=2;o {r(A[T],e,w),r(E[T],e,w)})),r(l._A,"fetch",y),t.on(y+"end",(function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(y+"done",[null,r],n)}else t.emit(y+"done",[e],n)})),t}const O={},j=["pushState","replaceState"];function S(e){const t=function(e){return(e||n.ee).get("history")}(e);return!l.il||O[t.debugId]++||(O[t.debugId]=1,s(t).inPlace(window.history,j,"-")),t}var P=r(3239);const C={},R=["appendChild","insertBefore","replaceChild"];function I(e){const t=function(e){return(e||n.ee).get("jsonp")}(e);if(!l.il||C[t.debugId])return t;C[t.debugId]=!0;var r=s(t),i=/[?&](?:callback|cb)=([^&#]+)/,o=/(.*)\.([^.]+)/,a=/^(\w+)(\.|$)(.*)$/;function c(e,t){var r=e.match(a),n=r[1],i=r[3];return i?c(i,t[n]):t[n]}return r.inPlace(Node.prototype,R,"dom-"),t.on("dom-start",(function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var n=(a=e.src,s=a.match(i),s?s[1]:null);var a,s;if(!n)return;var u=function(e){var t=e.match(o);if(t&&t.length>=3)return{key:t[2],parent:c(t[1],window)};return{key:e,parent:window}}(n);if("function"!=typeof u.parent[u.key])return;var d={};function f(){t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}function l(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",f,(0,P.m$)(!1)),e.addEventListener("error",l,(0,P.m$)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])})),t}var k=r(5763);const H={};function L(e){const t=function(e){return(e||n.ee).get("mutation")}(e);if(!l.il||H[t.debugId])return t;H[t.debugId]=!0;var r=s(t),i=k.Yu.MO;return i&&(window.MutationObserver=function(e){return this instanceof i?new i(r(e,"fn-")):i.apply(this,arguments)},MutationObserver.prototype=i.prototype),t}const z={};function M(e){const t=function(e){return(e||n.ee).get("promise")}(e);if(z[t.debugId])return t;z[t.debugId]=!0;var r=n.c,o=s(t),a=k.Yu.PR;return a&&function(){function e(r){var n=t.context(),i=o(r,"executor-",n,null,!1);const s=Reflect.construct(a,[i],e);return t.context(s).getCtx=function(){return n},s}l._A.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return a.toString()},Object.setPrototypeOf(e,a),["all","race"].forEach((function(r){const n=a[r];e[r]=function(e){let i=!1;[...e||[]].forEach((e=>{this.resolve(e).then(a("all"===r),a(!1))}));const o=n.apply(this,arguments);return o;function a(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}})),["resolve","reject"].forEach((function(r){const n=a[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}})),e.prototype=a.prototype;const n=a.prototype.then;a.prototype.then=function(){var e=this,i=r(e);i.promise=e;for(var a=arguments.length,s=new Array(a),c=0;c e())),t};function m(e,t){i.inPlace(t,["onreadystatechange"],"fn-",E)}function b(){var e=this,t=r.context(e);e.readyState>3&&!t.resolved&&(t.resolved=!0,r.emit("xhr-resolved",[],e)),i.inPlace(e,f,"fn-",E)}if(function(e,t){for(var r in e)t[r]=e[r]}(o,p),p.prototype=o.prototype,i.inPlace(p.prototype,J,"-xhr-",E),r.on("send-xhr-start",(function(e,t){m(e,t),function(e){h.push(e),a&&(y?y.then(A):u?u(A):(w=-w,x.data=w))}(t)})),r.on("open-xhr-start",m),a){var y=c&&c.resolve();if(!u&&!c){var w=1,x=document.createTextNode(w);new a(A).observe(x,{characterData:!0})}}else t.on("fn-end",(function(e){e[0]&&e[0].type===d||A()}));function A(){for(var e=0;e {r.d(t,{t:()=>n});const n=r(3325).D.ajax},6660:(e,t,r)=>{r.d(t,{A:()=>i,t:()=>n});const n=r(3325).D.jserrors,i="nr@seenError"},3081:(e,t,r)=>{r.d(t,{gF:()=>o,mY:()=>i,t9:()=>n,vz:()=>s,xS:()=>a});const n=r(3325).D.metrics,i="sm",o="cm",a="storeSupportabilityMetrics",s="storeEventMetrics"},4649:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageAction},7633:(e,t,r)=>{r.d(t,{Dz:()=>i,OJ:()=>a,qw:()=>o,t9:()=>n});const n=r(3325).D.pageViewEvent,i="firstbyte",o="domcontent",a="windowload"},9251:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageViewTiming},3614:(e,t,r)=>{r.d(t,{BST_RESOURCE:()=>i,END:()=>s,FEATURE_NAME:()=>n,FN_END:()=>u,FN_START:()=>c,PUSH_STATE:()=>d,RESOURCE:()=>o,START:()=>a});const n=r(3325).D.sessionTrace,i="bstResource",o="resource",a="-start",s="-end",c="fn"+a,u="fn"+s,d="pushState"},7836:(e,t,r)=>{r.d(t,{BODY:()=>A,CB_END:()=>E,CB_START:()=>u,END:()=>x,FEATURE_NAME:()=>i,FETCH:()=>_,FETCH_BODY:()=>v,FETCH_DONE:()=>m,FETCH_START:()=>p,FN_END:()=>c,FN_START:()=>s,INTERACTION:()=>l,INTERACTION_API:()=>d,INTERACTION_EVENTS:()=>o,JSONP_END:()=>b,JSONP_NODE:()=>g,JS_TIME:()=>T,MAX_TIMER_BUDGET:()=>a,REMAINING:()=>f,SPA_NODE:()=>h,START:()=>w,originalSetTimeout:()=>y});var n=r(5763);const i=r(3325).D.spa,o=["click","submit","keypress","keydown","keyup","change"],a=999,s="fn-start",c="fn-end",u="cb-start",d="api-ixn-",f="remaining",l="interaction",h="spaNode",g="jsonpNode",p="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=n.Yu.ST,w="-start",x="-end",A="-body",E="cb"+x,T="jsTime",_="fetch"},5938:(e,t,r)=>{r.d(t,{W:()=>o});var n=r(5763),i=r(2177);class o{constructor(e,t,r){this.agentIdentifier=e,this.aggregator=t,this.ee=i.ee.get(e,(0,n.OP)(this.agentIdentifier).isolatedBacklog),this.featureName=r,this.blocked=!1}}},9144:(e,t,r)=>{r.d(t,{j:()=>m});var n=r(3325),i=r(5763),o=r(5546),a=r(2177),s=r(7894),c=r(8e3),u=r(3960),d=r(385),f=r(50),l=r(3081),h=r(8632);function g(){const e=(0,h.gG)();["setErrorHandler","finished","addToTrace","inlineHit","addRelease","addPageAction","setCurrentRouteName","setPageViewName","setCustomAttribute","interaction","noticeError","setUserId"].forEach((t=>{e[t]=function(){for(var r=arguments.length,n=new Array(r),i=0;i 1?r-1:0),i=1;i {e.exposed&&e.api[t]&&o.push(e.api[t](...n))})),o.length>1?o:o[0]}(t,...n)}}))}var p=r(2587);function m(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},m=arguments.length>2?arguments[2]:void 0,v=arguments.length>3?arguments[3]:void 0,{init:b,info:y,loader_config:w,runtime:x={loaderType:m},exposed:A=!0}=t;const E=(0,h.gG)();y||(b=E.init,y=E.info,w=E.loader_config),(0,i.Dg)(e,b||{}),(0,i.GE)(e,w||{}),(0,i.sU)(e,x),y.jsAttributes??={},d.v6&&(y.jsAttributes.isWorker=!0),(0,i.CX)(e,y),g();const T=function(e,t){t||(0,c.R)(e,"api");const h={};var g=a.ee.get(e),p=g.get("tracer"),m="api-",v=m+"ixn-";function b(t,r,n,o){const a=(0,i.C5)(e);return null===r?delete a.jsAttributes[t]:(0,i.CX)(e,{...a,jsAttributes:{...a.jsAttributes,[t]:r}}),x(m,n,!0,o||null===r?"session":void 0)(t,r)}function y(){}["setErrorHandler","finished","addToTrace","inlineHit","addRelease"].forEach((e=>h[e]=x(m,e,!0,"api"))),h.addPageAction=x(m,"addPageAction",!0,n.D.pageAction),h.setCurrentRouteName=x(m,"routeName",!0,n.D.spa),h.setPageViewName=function(t,r){if("string"==typeof t)return"/"!==t.charAt(0)&&(t="/"+t),(0,i.OP)(e).customTransaction=(r||"http://custom.transaction")+t,x(m,"setPageViewName",!0)()},h.setCustomAttribute=function(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2];if("string"==typeof e){if(["string","number"].includes(typeof t)||null===t)return b(e,t,"setCustomAttribute",r);(0,f.Z)("Failed to execute setCustomAttribute.\nNon-null value must be a string or number type, but a type of was provided."))}else(0,f.Z)("Failed to execute setCustomAttribute.\nName must be a string type, but a type of was provided."))},h.setUserId=function(e){if("string"==typeof e||null===e)return b("enduser.id",e,"setUserId",!0);(0,f.Z)("Failed to execute setUserId.\nNon-null value must be a string type, but a type of was provided."))},h.interaction=function(){return(new y).get()};var w=y.prototype={createTracer:function(e,t){var r={},i=this,a="function"==typeof t;return(0,o.p)(v+"tracer",[(0,s.z)(),e,r],i,n.D.spa,g),function(){if(p.emit((a?"":"no-")+"fn-start",[(0,s.z)(),i,a],r),a)try{return t.apply(this,arguments)}catch(e){throw p.emit("fn-err",[arguments,this,"string"==typeof e?new Error(e):e],r),e}finally{p.emit("fn-end",[(0,s.z)()],r)}}}};function x(e,t,r,i){return function(){return(0,o.p)(l.xS,["API/"+t+"/called"],void 0,n.D.metrics,g),i&&(0,o.p)(e+t,[(0,s.z)(),...arguments],r?null:this,i,g),r?void 0:this}}function A(){r.e(439).then(r.bind(r,7438)).then((t=>{let{setAPI:r}=t;r(e),(0,c.L)(e,"api")})).catch((()=>(0,f.Z)("Downloading runtime APIs failed...")))}return["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach((e=>{w[e]=x(v,e,void 0,n.D.spa)})),h.noticeError=function(e,t){"string"==typeof e&&(e=new Error(e)),(0,o.p)(l.xS,["API/noticeError/called"],void 0,n.D.metrics,g),(0,o.p)("err",[e,(0,s.z)(),!1,t],void 0,n.D.jserrors,g)},d.il?(0,u.b)((()=>A()),!0):A(),h}(e,v);return(0,h.Qy)(e,T,"api"),(0,h.Qy)(e,A,"exposed"),(0,h.EZ)("activatedFeatures",p.T),T}},3325:(e,t,r)=>{r.d(t,{D:()=>n,p:()=>i});const n={ajax:"ajax",jserrors:"jserrors",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",spa:"spa"},i={[n.pageViewEvent]:1,[n.pageViewTiming]:2,[n.metrics]:3,[n.jserrors]:4,[n.ajax]:5,[n.sessionTrace]:6,[n.pageAction]:7,[n.spa]:8,[n.sessionReplay]:9}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce(((t,r)=>(i.f[r](e,t),t)),[])),i.u=e=>(({78:"page_action-aggregate",147:"metrics-aggregate",242:"session-manager",317:"jserrors-aggregate",348:"page_view_timing-aggregate",412:"lazy-feature-loader",439:"async-api",538:"recorder",590:"session_replay-aggregate",675:"compressor",733:"session_trace-aggregate",786:"page_view_event-aggregate",873:"spa-aggregate",898:"ajax-aggregate"}[e]||e)+"."+{78:"ac76d497",147:"3dc53903",148:"1a20d5fe",242:"2a64278a",317:"49e41428",348:"bd6de33a",412:"2f55ce66",439:"30bd804e",538:"1b18459f",590:"cf0efb30",675:"ae9f91a8",733:"83105561",786:"06482edd",860:"03a8b7a5",873:"e6b09d52",898:"998ef92b"}[e]+"-1.236.0.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA:",i.l=(r,n,o,a)=>{if(e[r])e[r].push(n);else{var s,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d {s.onerror=s.onload=null,clearTimeout(h);var i=e[r];if(delete e[r],s.parentNode&&s.parentNode.removeChild(s),i&&i.forEach((e=>e(n))),t)return t(n)},h=setTimeout(l.bind(null,void 0,{type:"timeout",target:s}),12e4);s.onerror=l.bind(null,s.onerror),s.onload=l.bind(null,s.onload),c&&document.head.appendChild(s)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.j=364,i.p="https://js-agent.newrelic.com/",(()=>{var e={364:0,953:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise(((r,i)=>n=e[t]=[r,i]));r.push(n[2]=o);var a=i.p+i.u(t),s=new Error;i.l(a,(r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),a=r&&r.target&&r.target.src;s.message="Loading chunk "+t+" failed.\n("+o+": "+a+")",s.name="ChunkLoadError",s.type=o,s.request=a,n[1](s)}}),"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[a,s,c]=r,u=0;if(a.some((t=>0!==e[t]))){for(n in s)i.o(s,n)&&(i.m[n]=s[n]);if(c)c(i)}for(t&&t(r);u {i.r(o);var e=i(3325),t=i(5763);const r=Object.values(e.D);function n(e){const n={};return r.forEach((r=>{n[r]=function(e,r){return!1!==(0,t.Mt)(r,"".concat(e,".enabled"))}(r,e)})),n}var a=i(9144);var s=i(5546),c=i(385),u=i(8e3),d=i(5938),f=i(3960),l=i(50);class h extends d.W{constructor(e,t,r){let n=!(arguments.length>3&&void 0!==arguments[3])||arguments[3];super(e,t,r),this.auto=n,this.abortHandler,this.featAggregate,this.onAggregateImported,n&&(0,u.R)(e,r)}importAggregator(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{};if(this.featAggregate||!this.auto)return;const r=c.il&&!0===(0,t.Mt)(this.agentIdentifier,"privacy.cookies_enabled");let n;this.onAggregateImported=new Promise((e=>{n=e}));const o=async()=>{let t;try{if(r){const{setupAgentSession:e}=await Promise.all([i.e(860),i.e(242)]).then(i.bind(i,3228));t=e(this.agentIdentifier)}}catch(e){(0,l.Z)("A problem occurred when starting up session manager. This page will not start or extend any session.",e)}try{if(!this.shouldImportAgg(this.featureName,t))return void(0,u.L)(this.agentIdentifier,this.featureName);const{lazyFeatureLoader:r}=await i.e(412).then(i.bind(i,8582)),{Aggregate:o}=await r(this.featureName,"aggregate");this.featAggregate=new o(this.agentIdentifier,this.aggregator,e),n(!0)}catch(e){(0,l.Z)("Downloading and initializing ".concat(this.featureName," failed..."),e),this.abortHandler?.(),n(!1)}};c.il?(0,f.b)((()=>o()),!0):o()}shouldImportAgg(r,n){return r!==e.D.sessionReplay||!1!==(0,t.Mt)(this.agentIdentifier,"session_trace.enabled")&&(!!n?.isNew||!!n?.state.sessionReplay)}}var g=i(7633),p=i(7894);class m extends h{static featureName=g.t9;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];if(super(r,n,g.t9,i),("undefined"==typeof PerformanceNavigationTiming||c.Tt)&&"undefined"!=typeof PerformanceTiming){const n=(0,t.OP)(r);n[g.Dz]=Math.max(Date.now()-n.offset,0),(0,f.K)((()=>n[g.qw]=Math.max((0,p.z)()-n[g.Dz],0))),(0,f.b)((()=>{const t=(0,p.z)();n[g.OJ]=Math.max(t-n[g.Dz],0),(0,s.p)("timing",["load",t],void 0,e.D.pageViewTiming,this.ee)}))}this.importAggregator()}}var v=i(1117),b=i(1284);class y extends v.w{constructor(e){super(e),this.aggregatedData={}}store(e,t,r,n,i){var o=this.getBucket(e,t,r,i);return o.metrics=function(e,t){t||(t={count:0});return t.count+=1,(0,b.D)(e,(function(e,r){t[e]=w(r,t[e])})),t}(n,o.metrics),o}merge(e,t,r,n,i){var o=this.getBucket(e,t,n,i);if(o.metrics){var a=o.metrics;a.count+=r.count,(0,b.D)(r,(function(e,t){if("count"!==e){var n=a[e],i=r[e];i&&!i.c?a[e]=w(i.t,n):a[e]=function(e,t){if(!t)return e;t.c||(t=x(t.t));return t.min=Math.min(e.min,t.min),t.max=Math.max(e.max,t.max),t.t+=e.t,t.sos+=e.sos,t.c+=e.c,t}(i,a[e])}}))}else o.metrics=r}storeMetric(e,t,r,n){var i=this.getBucket(e,t,r);return i.stats=w(n,i.stats),i}getBucket(e,t,r,n){this.aggregatedData[e]||(this.aggregatedData[e]={});var i=this.aggregatedData[e][t];return i||(i=this.aggregatedData[e][t]={params:r||{}},n&&(i.custom=n)),i}get(e,t){return t?this.aggregatedData[e]&&this.aggregatedData[e][t]:this.aggregatedData[e]}take(e){for(var t={},r="",n=!1,i=0;i t.max&&(t.max=e),e 2&&void 0!==arguments[2])||arguments[2];super(e,r,j.t,n),c.il&&((0,t.OP)(e).initHidden=Boolean("hidden"===document.visibilityState),(0,N.N)((()=>(0,s.p)("docHidden",[(0,p.z)()],void 0,j.t,this.ee)),!0),(0,O.bP)("pagehide",(()=>(0,s.p)("winPagehide",[(0,p.z)()],void 0,j.t,this.ee))),this.importAggregator())}}var P=i(3081);class C extends h{static featureName=P.t9;constructor(e,t){let r=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(e,t,P.t9,r),this.importAggregator()}}var R,I=i(2210),k=i(1214),H=i(2177),L={};try{R=localStorage.getItem("__nr_flags").split(","),console&&"function"==typeof console.log&&(L.console=!0,-1!==R.indexOf("dev")&&(L.dev=!0),-1!==R.indexOf("nr_dev")&&(L.nrDev=!0))}catch(e){}function z(e){try{L.console&&z(e)}catch(e){}}L.nrDev&&H.ee.on("internal-error",(function(e){z(e.stack)})),L.dev&&H.ee.on("fn-err",(function(e,t,r){z(r.stack)})),L.dev&&(z("NR AGENT IN DEVELOPMENT MODE"),z("flags: "+(0,b.D)(L,(function(e,t){return e})).join(", ")));var M=i(6660);class B extends h{static featureName=M.t;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(r,n,M.t,i),this.skipNext=0;try{this.removeOnAbort=new AbortController}catch(e){}const o=this;o.ee.on("fn-start",(function(e,t,r){o.abortHandler&&(o.skipNext+=1)})),o.ee.on("fn-err",(function(t,r,n){o.abortHandler&&!n[M.A]&&((0,I.X)(n,M.A,(function(){return!0})),this.thrown=!0,(0,s.p)("err",[n,(0,p.z)()],void 0,e.D.jserrors,o.ee))})),o.ee.on("fn-end",(function(){o.abortHandler&&!this.thrown&&o.skipNext>0&&(o.skipNext-=1)})),o.ee.on("internal-error",(function(t){(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,o.ee)})),this.origOnerror=c._A.onerror,c._A.onerror=this.onerrorHandler.bind(this),c._A.addEventListener("unhandledrejection",(t=>{const r=function(e){let t="Unhandled Promise Rejection: ";if(e instanceof Error)try{return e.message=t+e.message,e}catch(t){return e}if(void 0===e)return new Error(t);try{return new Error(t+(0,D.P)(e))}catch(e){return new Error(t)}}(t.reason);(0,s.p)("err",[r,(0,p.z)(),!1,{unhandledPromiseRejection:1}],void 0,e.D.jserrors,this.ee)}),(0,O.m$)(!1,this.removeOnAbort?.signal)),(0,k.gy)(this.ee),(0,k.BV)(this.ee),(0,k.em)(this.ee),(0,t.OP)(r).xhrWrappable&&(0,k.Kf)(this.ee),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}onerrorHandler(t,r,n,i,o){"function"==typeof this.origOnerror&&this.origOnerror(...arguments);try{this.skipNext?this.skipNext-=1:(0,s.p)("err",[o||new F(t,r,n),(0,p.z)()],void 0,e.D.jserrors,this.ee)}catch(t){try{(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,this.ee)}catch(e){}}return!1}}function F(e,t,r){this.message=e||"Uncaught error with no additional information",this.sourceURL=t,this.line=r}let U=1;const q="nr@id";function G(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===c._A?0:(0,I.X)(e,q,(function(){return U++}))}function V(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,D.P)(e).length}catch(e){return}}}var X=i(7243);class W{constructor(e){this.agentIdentifier=e,this.generateTracePayload=this.generateTracePayload.bind(this),this.shouldGenerateTrace=this.shouldGenerateTrace.bind(this)}generateTracePayload(e){if(!this.shouldGenerateTrace(e))return null;var r=(0,t.DL)(this.agentIdentifier);if(!r)return null;var n=(r.accountID||"").toString()||null,i=(r.agentID||"").toString()||null,o=(r.trustKey||"").toString()||null;if(!n||!i)return null;var a=(0,_.M)(),s=(0,_.Ht)(),c=Date.now(),u={spanId:a,traceId:s,timestamp:c};return(e.sameOrigin||this.isAllowedOrigin(e)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(a,s),u.traceContextStateHeader=this.generateTraceContextStateHeader(a,c,n,i,o)),(e.sameOrigin&&!this.excludeNewrelicHeader()||!e.sameOrigin&&this.isAllowedOrigin(e)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(a,s,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof c._A?.btoa))return null;var a={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(a.d.tk=o),btoa((0,D.P)(a))}shouldGenerateTrace(e){return this.isDtEnabled()&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var r=!1,n={};if((0,t.Mt)(this.agentIdentifier,"distributed_tracing")&&(n=(0,t.P_)(this.agentIdentifier).distributed_tracing),e.sameOrigin)r=!0;else if(n.allowed_origins instanceof Array)for(var i=0;i 2&&void 0!==arguments[2])||arguments[2];super(r,n,Z.t,i),(0,t.OP)(r).xhrWrappable&&(this.dt=new W(r),this.handler=(e,t,r,n)=>(0,s.p)(e,t,r,n,this.ee),(0,k.u5)(this.ee),(0,k.Kf)(this.ee),function(r,n,i,o){function a(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=E,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},e.addEventListener("load",(function(r){_(t,e)}),(0,O.m$)(!1)),c.IF||e.addEventListener("progress",(function(e){t.lastSize=e.loaded}),(0,O.m$)(!1))}function s(e){this.params={method:e[0]},T(this,e[1]),this.metrics={}}function u(e,n){var i=(0,t.DL)(r);i.xpid&&this.sameOrigin&&n.setRequestHeader("X-NewRelic-ID",i.xpid);var a=o.generateTracePayload(this.parsedOrigin);if(a){var s=!1;a.newrelicHeader&&(n.setRequestHeader("newrelic",a.newrelicHeader),s=!0),a.traceContextParentHeader&&(n.setRequestHeader("traceparent",a.traceContextParentHeader),a.traceContextStateHeader&&n.setRequestHeader("tracestate",a.traceContextStateHeader),s=!0),s&&(this.dt=a)}}function d(e,t){var r=this.metrics,i=e[0],o=this;if(r&&i){var a=V(i);a&&(r.txSize=a)}this.startTime=(0,p.z)(),this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof t.onload)&&"function"==typeof o.end)&&o.end(t)}catch(e){try{n.emit("internal-error",[e])}catch(e){}}};for(var s=0;s 1?e[1]=i:e.push(i)}else e[0]&&e[0].headers&&s(e[0].headers,n)&&(this.dt=n);function s(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,p.z)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r,n=this.opts||{},i=this.target;"string"==typeof i?r=i:"object"==typeof i&&i instanceof Y?r=i.url:c._A?.URL&&"object"==typeof i&&i instanceof URL&&(r=i.href),T(this,r);var o=(""+(i&&i instanceof Y&&i.method||n.method||"GET")).toUpperCase();this.params.method=o,this.txSize=V(n.body)||0}function A(t,r){var n;this.endTime=(0,p.z)(),this.params||(this.params={}),this.params.status=r?r.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(n=+this.rxSize);var o={txSize:this.txSize,rxSize:n,duration:(0,p.z)()-this.startTime};i("xhr",[this.params,o,this.startTime,this.endTime,"fetch"],this,e.D.ajax)}function E(t){var r=this.params,n=this.metrics;if(!this.ended){this.ended=!0;for(var o=0;o 2&&void 0!==arguments[2])||arguments[2];super(e,t,we.t,r),this.importAggregator()}}new class{constructor(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:(0,_.ky)(16);c._A?(this.agentIdentifier=t,this.sharedAggregator=new y({agentIdentifier:this.agentIdentifier}),this.features={},this.desiredFeatures=new Set(e.features||[]),this.desiredFeatures.add(m),Object.assign(this,(0,a.j)(this.agentIdentifier,e,e.loaderType||"agent")),this.start()):(0,l.Z)("Failed to initial the agent. Could not determine the runtime environment.")}get config(){return{info:(0,t.C5)(this.agentIdentifier),init:(0,t.P_)(this.agentIdentifier),loader_config:(0,t.DL)(this.agentIdentifier),runtime:(0,t.OP)(this.agentIdentifier)}}start(){const t="features";try{const r=n(this.agentIdentifier),i=[...this.desiredFeatures];i.sort(((t,r)=>e.p[t.featureName]-e.p[r.featureName])),i.forEach((t=>{if(r[t.featureName]||t.featureName===e.D.pageViewEvent){const n=function(t){switch(t){case e.D.ajax:return[e.D.jserrors];case e.D.sessionTrace:return[e.D.ajax,e.D.pageViewEvent];case e.D.sessionReplay:return[e.D.sessionTrace];case e.D.pageViewTiming:return[e.D.pageViewEvent];default:return[]}}(t.featureName);n.every((e=>r[e]))||(0,l.Z)("".concat(t.featureName," is enabled but one or more dependent features has been disabled (").concat((0,D.P)(n),"). This may cause unintended consequences or missing data...")),this.features[t.featureName]=new t(this.agentIdentifier,this.sharedAggregator)}})),(0,T.Qy)(this.agentIdentifier,this.features,t)}catch(e){(0,l.Z)("Failed to initialize all enabled instrument classes (agent aborted) -",e);for(const e in this.features)this.features[e].abortHandler?.();const r=(0,T.fP)();return delete r.initializedAgents[this.agentIdentifier]?.api,delete r.initializedAgents[this.agentIdentifier]?.[t],delete this.sharedAggregator,r.ee?.abort(),delete r.ee?.get(this.agentIdentifier),!1}}}({features:[J,m,S,class extends h{static featureName=oe;constructor(t,r){if(super(t,r,oe,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;const n=this.ee;let i;(0,k.QU)(n),this.eventsEE=(0,k.em)(n),this.eventsEE.on(se,(function(e,t){this.bstStart=(0,p.z)()})),this.eventsEE.on(ae,(function(t,r){(0,s.p)("bst",[t[0],r,this.bstStart,(0,p.z)()],void 0,e.D.sessionTrace,n)})),n.on(ce+ne,(function(e){this.time=(0,p.z)(),this.startPath=location.pathname+location.hash})),n.on(ce+ie,(function(t){(0,s.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,e.D.sessionTrace,n)}));try{i=new PerformanceObserver((t=>{const r=t.getEntries();(0,s.p)(te,[r],void 0,e.D.sessionTrace,n)})),i.observe({type:re,buffered:!0})}catch(e){}this.importAggregator({resourceObserver:i})}},C,xe,B,class extends h{static featureName=de;constructor(e,r){if(super(e,r,de,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;if(!(0,t.OP)(e).xhrWrappable)return;try{this.removeOnAbort=new AbortController}catch(e){}let n,i=0;const o=this.ee.get("tracer"),a=(0,k._L)(this.ee),s=(0,k.Lg)(this.ee),u=(0,k.BV)(this.ee),d=(0,k.Kf)(this.ee),f=this.ee.get("events"),l=(0,k.u5)(this.ee),h=(0,k.QU)(this.ee),g=(0,k.Gm)(this.ee);function m(e,t){h.emit("newURL",[""+window.location,t])}function v(){i++,n=window.location.hash,this[ve]=(0,p.z)()}function b(){i--,window.location.hash!==n&&m(0,!0);var e=(0,p.z)();this[pe]=~~this[pe]+e-this[ve],this[ye]=e}function y(e,t){e.on(t,(function(){this[t]=(0,p.z)()}))}this.ee.on(ve,v),s.on(be,v),a.on(be,v),this.ee.on(ye,b),s.on(ge,b),a.on(ge,b),this.ee.buffer([ve,ye,"xhr-resolved"],this.featureName),f.buffer([ve],this.featureName),u.buffer(["setTimeout"+le,"clearTimeout"+fe,ve],this.featureName),d.buffer([ve,"new-xhr","send-xhr"+fe],this.featureName),l.buffer([me+fe,me+"-done",me+he+fe,me+he+le],this.featureName),h.buffer(["newURL"],this.featureName),g.buffer([ve],this.featureName),s.buffer(["propagate",be,ge,"executor-err","resolve"+fe],this.featureName),o.buffer([ve,"no-"+ve],this.featureName),a.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),y(l,me+fe),y(l,me+"-done"),y(a,"new-jsonp"),y(a,"jsonp-end"),y(a,"cb-start"),h.on("pushState-end",m),h.on("replaceState-end",m),window.addEventListener("hashchange",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",(function(){m(0,i>1)}),(0,O.m$)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}],loaderType:"spa"})})(),window.NRBA=o})(); window.jQuery || document.write(' ') CKEDITOR_BASEPATH='https://f1000research.com/js/vendor/ckeditor/' window.reactTheme = 'research'; window.MathJax = { CommonHTML: { linebreaks: { automatic: true } }, 'HTML-CSS': { linebreaks: { automatic: true } }, SVG: { linebreaks: { automatic: true } }, AuthorInit: function() { MathJax.Hub.Register.MessageHook('End Process', function () { let timeout = false; // holder for timeout id const delay = 250; // delay after event is "complete" to run callback const reflowMath = function() { const dispFormulas = document.querySelectorAll('.disp-formula.panel'); if (!dispFormulas) { return; } for (const dispFormula of dispFormulas) { const child = dispFormula.querySelector('.MathJax_Preview').nextSibling.firstChild; const isMultiline = MathJax.Hub.getAllJax(dispFormula)[0].root.isMultiline; if (dispFormula.offsetWidth < child.offsetWidth || isMultiline) { MathJax.Hub.Queue(['Rerender', MathJax.Hub, dispFormula]); } } }; window.addEventListener('resize', function() { clearTimeout(timeout); // clear the timeout timeout = setTimeout(reflowMath, delay); // start timing for event "completion" }); }); }, }; if (window.location.hash == '#_=_'){ window.location = window.location.href.split('#')[0] } !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function() {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)} ;if(!f._fbq)f._fbq=n; n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0; t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window, document,'script','https://connect.facebook.net/en_US/fbevents.js'); fbq('init', '1641728616063202'); fbq('track', "PixelInitialized", {}); (function(h,o,t,j,a,r){ h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)}; h._hjSettings={hjid:2318163,hjsv:6}; a=o.getElementsByTagName('head')[0]; r=o.createElement('script');r.async=1; r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv; a.appendChild(r); })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv='); search file_upload Submit your research search menu close search Browse Gateways & Collections How to Publish Submit your Research My Submissions Article Guidelines Article Guidelines (New Versions) Open Data, Software and Code Guidelines Open Data and Accessible Source Materials Guidelines (HSS) Open Data, Software and Code Guidelines (PSE) Prepublication Checks Production Process Posters and Slides Guidelines Document Guidelines Article Processing Charges Peer Review Finding Article Reviewers About How it Works For Reviewers Our Advisors Policies Glossary FAQs For Developers Newsroom Contact My Research Submissions Content and Tracking Alerts My Details Sign In file_upload Submit your research { "@context": "https://schema.org", "@type": "ScholarlyArticle", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://f1000research.com/articles/13-46" }, "headline": "Strengthening of CYFRA 21-1 using urine creatinine correction as potential endometriosis biomarker ", "datePublished": "2024-01-08T11:23:03", "dateModified": "2025-05-14T09:51:08", "author": [ { "@type": "Person", "name": "Nicko Pisceski Kusika Saputra" }, { "@type": "Person", "name": "Samsulhadi Samsulhadi" }, { "@type": "Person", "name": "Hendy Hendarto" }, { "@type": "Person", "name": "Ashon Sa’adi" }, { "@type": "Person", "name": "Widodo J Pudjirahardjo" }, { "@type": "Person", "name": "I Wayan Arsana" }, { "@type": "Person", "name": "Relly Yanuari" }, { "@type": "Person", "name": "Sri Ratna Dwiningsih" } ], "publisher": { "@type": "Organization", "name": "F1000Research", "logo": { "@type": "ImageObject", "url": "https://f1000research.com/img/AMP/F1000Research_image.png", "height": 480, "width": 60 } }, "image": { "@type": "ImageObject", "url": "https://f1000research.com/img/AMP/F1000Research_image.png", "height": 1200, "width": 150 }, "description": " Background This study aimed to determine the accuracy of CYFRA 21-1 using urine creatinine correction (CYFRA/Cr) as a biomarker of endometriosis. Methods This study includes 73 patients from the Indonesian population, with 38 endometriosis and 35 non-endometriosis patients based on laparoscopy. Urine detection of CYFRA 21-1 was done by ELISA method and corrected by urine creatinine constant factor (CYFRA/Cr). Urine creatinine us detected using the ECLIA method. Results The CYFRA/Cr ratio was identified in the proliferative and secretory phases. CYFRA 21-1 and CYFRA/Cr levels were significantly higher in endometriosis and were higher in the proliferative phase compared to the secretory phase. The best accuracy was obtained in CYFRA which was corrected with urine creatinine in the proliferative phase with a sensitivity value, specificity, and cutoff value of 94.7%, 94.4%, and of 3,547.99 ng/gr, respectively, compared to CYFRA 21-1 urine levels without correction of creatinine. Conclusions The CYFRA to creatinine urine ratio detected in the proliferative phase showed the optimum sensitivity and specificity compared to CYFRA 21-1 spot urine. It has the potential to be a biomarker of endometriosis. " } { "@context": "http://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": "1", "item": { "@id": "https://f1000research.com/", "name": "Home" } }, { "@type": "ListItem", "position": "2", "item": { "@id": "https://f1000research.com/browse/articles", "name": "Browse" } }, { "@type": "ListItem", "position": "3", "item": { "@id": "https://f1000research.com/articles/13-46/v1", "name": "Strengthening of CYFRA 21-1 using urine creatinine correction as potential..." } } ] } Home Browse Strengthening of CYFRA 21-1 using urine creatinine correction as potential... ALL Metrics - Views Downloads Get PDF Get XML Cite How to cite this article Saputra NPK, Samsulhadi S, Hendarto H et al. Strengthening of CYFRA 21-1 using urine creatinine correction as potential endometriosis biomarker [version 1; peer review: 1 approved, 1 approved with reservations] . F1000Research 2024, 13 :46 ( https://doi.org/10.12688/f1000research.135167.1 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. Close Copy Citation Details Export Export Citation Sciwheel EndNote Ref. Manager Bibtex ProCite Sente EXPORT Select a format first Track Share ▬ ✚ Research Article Strengthening of CYFRA 21-1 using urine creatinine correction as potential endometriosis biomarker [version 1; peer review: 1 approved, 1 approved with reservations] Nicko Pisceski Kusika Saputra https://orcid.org/0000-0003-4431-4565 1,2 , Samsulhadi Samsulhadi 2 , Hendy Hendarto https://orcid.org/0000-0002-9585-4775 2 , [...] Ashon Sa’adi 2 , Widodo J Pudjirahardjo 3 , I Wayan Arsana https://orcid.org/0000-0002-4922-588X 4 , Relly Yanuari 2 , Sri Ratna Dwiningsih 2 Nicko Pisceski Kusika Saputra https://orcid.org/0000-0003-4431-4565 1,2 , Samsulhadi Samsulhadi 2 , [...] Hendy Hendarto https://orcid.org/0000-0002-9585-4775 2 , Ashon Sa’adi 2 , Widodo J Pudjirahardjo 3 , I Wayan Arsana https://orcid.org/0000-0002-4922-588X 4 , Relly Yanuari 2 , Sri Ratna Dwiningsih 2 PUBLISHED 08 Jan 2024 Author details Author details 1 Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Riau, Pekanbaru, Riau, Indonesia 2 Fertility and Reproductive Endocrinology Division, Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, Indonesia 3 Department of Public Health, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, Indonesia 4 Fertility and Endocrinology Division, Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Brawijaya, Malang, East Java, Indonesia Nicko Pisceski Kusika Saputra Roles: Conceptualization, Methodology, Validation, Writing – Original Draft Preparation Samsulhadi Samsulhadi Roles: Investigation, Software, Writing – Original Draft Preparation Hendy Hendarto Roles: Data Curation, Methodology, Writing – Original Draft Preparation Ashon Sa’adi Roles: Formal Analysis, Supervision, Writing – Original Draft Preparation Widodo J Pudjirahardjo Roles: Project Administration, Validation, Writing – Review & Editing I Wayan Arsana Roles: Methodology, Visualization, Writing – Review & Editing Relly Yanuari Roles: Formal Analysis, Supervision, Writing – Review & Editing Sri Ratna Dwiningsih Roles: Supervision, Validation, Writing – Review & Editing OPEN PEER REVIEW DETAILS REVIEWER STATUS This article is included in the Endometriosis collection. Abstract Background This study aimed to determine the accuracy of CYFRA 21-1 using urine creatinine correction (CYFRA/Cr) as a biomarker of endometriosis. Methods This study includes 73 patients from the Indonesian population, with 38 endometriosis and 35 non-endometriosis patients based on laparoscopy. Urine detection of CYFRA 21-1 was done by ELISA method and corrected by urine creatinine constant factor (CYFRA/Cr). Urine creatinine us detected using the ECLIA method. Results The CYFRA/Cr ratio was identified in the proliferative and secretory phases. CYFRA 21-1 and CYFRA/Cr levels were significantly higher in endometriosis and were higher in the proliferative phase compared to the secretory phase. The best accuracy was obtained in CYFRA which was corrected with urine creatinine in the proliferative phase with a sensitivity value, specificity, and cutoff value of 94.7%, 94.4%, and of 3,547.99 ng/gr, respectively, compared to CYFRA 21-1 urine levels without correction of creatinine. Conclusions The CYFRA to creatinine urine ratio detected in the proliferative phase showed the optimum sensitivity and specificity compared to CYFRA 21-1 spot urine. It has the potential to be a biomarker of endometriosis. READ ALL READ LESS Keywords Endometriosis, CYFRA 21-1, CYFRA/Cr, Urine Creatinine, Proliferative phase. Corresponding Author(s) Hendy Hendarto ( [email protected] ) Close Corresponding author: Hendy Hendarto Competing interests: No competing interests were disclosed. Grant information: The author(s) declared that no grants were involved in supporting this work. Copyright: © 2024 Saputra NPK et al . This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. How to cite: Saputra NPK, Samsulhadi S, Hendarto H et al. Strengthening of CYFRA 21-1 using urine creatinine correction as potential endometriosis biomarker [version 1; peer review: 1 approved, 1 approved with reservations] . F1000Research 2024, 13 :46 ( https://doi.org/10.12688/f1000research.135167.1 ) First published: 08 Jan 2024, 13 :46 ( https://doi.org/10.12688/f1000research.135167.1 ) Latest published: 14 May 2025, 13 :46 ( https://doi.org/10.12688/f1000research.135167.2 )  There is a newer version of this article available. Suppress this message for one day. Introduction The diagnosis of endometriosis is reported to be delayed to almost 7–10 years from disease onset because menstrual pain is often considered normal ( Hogg & Vyas, 2015 ). Laparoscopy is the gold standard for the diagnosis of endometriosis ( Tokushige et al. , 2011 ). Compared with histopathology, laparoscopy gave a sensitivity and specificity of 97.68% and 79.23%, respectively, in the diagnosis of endometriosis ( de Almeida Filho et al. , 2008 ). In another study, sensitivity was 94% (95% CI: 80%–98%), and specificity was 79% (95% CI: 67%–87%) ( Wykes et al. , 2004 ). However, laparoscopic surgery is an invasive procedure that sometimes provides unwanted complications and higher costs, causing a delay in the diagnosis and management of endometriosis ( Tokushige et al. , 2011 ). Biomarker detection as a diagnosis is very interesting and can advance the management of infertility and pelvic pain. Previous studies have identified endometriosis biomarkers from various samples, including blood, cervical mucus, and urine ( Fassbender et al. , 2015 ). Diagnosis with biomarkers is very promising because it is not invasive, relatively inexpensive, and relatively fast compared to surgery. Urine is a potential specimen in the diagnosis of endometriosis, especially urine biomarkers. In 2011, the protein that was found in the urine of endometriosis patients was identified as a cytokeratin-19 fragment, namely, CYFRA 21-1 ( Tokushige et al. , 2011 ). Cytokeratin-19 is found in simple and complex squamous cell epithelium, so it is commonly found in basal cells and squamous membranes. Cytokeratin-19 is a low molecular weight cytokeratin (LMWCK) ( Jose et al. , 2013 ). It is an acidic cytokeratin with a molecular weight of 40 kDa and is expressed in glandular-type epithelium, one of which is the endometrial gland epithelium ( Schweizer et al. , 2006 ). Although the mechanism of excretion of cytokeratin-19 fragments (CYFRA 21-1) in the urine is not clear, the presence of impaired renal filtration which is characterized by increasing serum creatinine levels that cause decreasing in the level of cytokeratin-19 fragments (CYFRA 21-1) in the urine accompanied the increasing its serum level in urine ( Kashiwabara et al. , 1998 ). The mean levels of cytokeratin-19 fragments (CYFRA 21-1) were significantly higher in the proliferative phase than in the secretory phase. The sensitivity value in the proliferative phase is 94.12%, with a cutoff value of 4 ng/ml/g creatinine, while the sensitivity value in the secretory phase is 31.5% ( Gjavotchanoff, 2015 ). However, CYFRA 21-1 as a biomarker is still inconclusive, so further study is needed to confirm this finding ( Liu et al. , 2015 ). The inconsistency of results may be due to unstable CYFRA 21-1 and heavily influenced by temperature, menstrual cycle, and fluctuating levels. Protein that is excreted into the urine is very volatile. Therefore, the description of spot urine protein levels can automatically describe the actual condition. When examining, routine urine protein levels must be compared with something relatively stable in the urine ( Kamińska et al. , 2020 ). The levels of cytokeratin-19 fragments (CYFRA 21-1) are circadian ( Gjavotchanoff, 2015 ; Nolen et al. , 2015 ). Urine creatinine is a determinant and correction factor that can be used because its levels are relatively stable in the urine; thus, the results obtained are not influenced by variations in fluid intake. This becomes the background for measuring spot urine protein levels. The standard for measuring urine protein is 24-h urine protein due to fluctuating protein excretion. However, the 24-h urine collection has many problems, so an alternative method can be used, i.e., the urine protein and creatinine ratio recommended by the National Kidney Foundation and Kidney Disease Outcomes Global Improving (KDIGO) ( National Kidney Foundation, 2002 ). Muscle metabolism leads to the irreversible dehydration of body creatine and creatine phosphate and creates creatinine as a waste product. More than 90% of the creatinine is accumulated in skeletal muscle. The formation rate of this product is constant; 2% of body creatine is converted to creatinine every 24 hours. However, the older the individual, the slower the rate ( Barr et al. , 2005 ). The inconsistency of study results needs to be reanalyzed to strengthen the potential of CYFRA 21-1 as a biomarker of endometriosis by using correction of urine creatinine to urine CYFRA (CYFRA/Cr). Therefore, this study aimed to analyze the accuracy of CYFRA 21-1 through urine creatinine correction for the diagnosis of endometriosis. Analysis was also carried out based on menstrual cycle. Methods Ethics and consent considerations This study has passed the ethical review of the Medical and Health Research Ethics Unit of the Faculty of Medicine, Universitas Riau with register number B/091/UN19.5.1.1.8/UEPKK/2021. It was declared to be ethically appropriate to seven WHO 2011 standards. The date of the certificate was 10 th September 2021. We confirm that we have obtained permission to use the data from the patients included in this presentation. Each patient gave written and verbal informed consent after they have been informed about the research’s objective, what was sampled and its procedure, as well as the provided data usage in this research. The patients also knew that this research would be published but no identifiable data from the patients would be included in the publication. Study design This is an analytic study with a cross-sectional design. The study was conducted at the Arifin Ahmad General Hospital, Provinsi Riau, from October 2019 to October 2021. Examination of cytokeratin-19 fragment (CYFRA 21-1) levels in urine was conducted at the Integrated Biomedical Laboratory, Faculty of Medicine, Universitas Riau, Indonesia. Examination of urine creatinine levels was conducted at the Prodia Laboratory Pekanbaru, Indonesia. Sample selection This study included all patients from the Fertility Clinic of Arifin Ahmad General Hospital with indications of laparoscopic surgery. The patients were approached directly when they were visiting in-person to the clinic and categorized based on the inclusion and exclusion criteria. The inclusion criteria were age of 30–40 years, normal body mass index (BMI) of 18.5–24.9 kg/m 2 , and menstrual cycle of 26–38 days. Age and BMI information was procured from anamnesis and direct observation when the patients were in the clinic. Information on the patient’s menstrual cycle was obtained during the observation at the clinic in the form of last day of menstruation. The menstrual cycle information was then analysed for its proliferation and secretion phase. The exclusion criteria were patients taking hormonal drugs such as contraception, other medications such as anti-inflammatory drugs, and antioxidant drugs and patients currently suffering from lung cancer, gastrointestinal cancer, urinary tract infections (based on the results of medical records, chest X-ray, urine routine examination, liver function), impaired kidney function (based on glomerular filtration rate (GFR), creatinine examination), and diabetes mellitus. A total of 73 patients were selected based on laparoscopy, with 38 endometriosis patients and 35 non-endometriosis patients. Urine CYFRA 21-1 levels test The ELISA method was used to examine the urine CYFRA 21-1 level. Urine was collected before laparoscopy and stored on ice or refrigerator for no more than 2 h before processing. During transport to the laboratory, the cold chain must be well maintained; hence the samples were transported using an icebox. The collected urine was stored in a refrigerator at −80°C before the examination. The urine used was uncentrifuged urine. The ELISA kit used is the Human Cytokeratin 19 ELISA Kit (product number RAB1409). Standard serial dilution was performed to obtain the following concentrations of CYFRA 21-1: 0.061 ng/ml, 0.154 ng/ml, 0.384 ng/ml, 0.960 ng/ml, 2.4 ng/ml, 6 ng/ml, 15 ng/ml, and blank. All reagents and samples were brought to room temperature (18–25°C) before use. Examination was performed in duplicate. Approximately 100 ul of each standard and sample was added to the well. The wells were covered and incubated for one night at a temperature of 4°C, followed by washing. Approximately 100 ul antibody was added to each well and incubated for 1 h at room temperature, mixed thoroughly, and washed. Approximately 100 ul of streptavidin was added and incubated for 45 min followed by washing. Approximately 100 ul of TMB substrate was added to each well, 50 ul of stop solution was added. The absorbance value was read at a wavelength of 450 nm. Standard plotting was performed to determine the equation on the standard curve. Urine creatinine and urine CYFRA/Cr ratio test Urine creatinine is a constant determinant in determining urine cytokeratin-12 levels, so the ratio of cytokeratin and urine creatinine can be identified. The ECLIA method was used to examine the urine creatinine level at the Prodia Pekanbaru Laboratory. The ratio of urine cytokeratin-19 fragment (CYFRA 21-1) levels to creatinine (CYFRA/Cr) was calculated by comparing the levels of cytokeratin-19 fragments (CYFRA21-1) to urine creatinine levels in ng/g units. Data analysis All data were processed using IBM SPSS Statistics 28.0. Numerical data was tested for data normality using the Kolmogorov–Smirnov and Shapiro–Wilk tests. Patient characteristics were analyzed using T-test and the Mann–Whitney test. Sensitivity and specificity tests for urinary cytokeratin-19 (CYFRA 21-1) and CYFRA/Cr levels were analyzed using the ROC test. The AUC values and coordinates of the curve were transformed into Microsoft Excel, and the data was then entered into a graph line with a marker to obtain the intersection point or cutoff point value of sensitivity and specificity. Results Table 1 presents the characteristics of the study subjects, consisting of age, BMI, and kidney function based on serum creatinine and GFR values. As presented in Table 1 , no differences were found in patient characteristics analyzed by cycle phase in both endometriosis and non-endometriosis cases. Based on serum creatinine and GFR data, it was found that all study subjects were in the normal range, which means that kidney function was in good condition. Therefore, the bias toward the excretion of cytokeratin-19 fragments (CYFRA 21-1) was negligible. Based on the results of chest X-ray examination in all study subjects, the heart and lungs were within normal limits. Based on examination of blood sugar, liver function, and routine urine, all samples were found to be within normal limits so they could be included. Table 1. Patient characteristics. Characteristics N Cycle phase Mean ± SD Median (Min–Max) p Non-endometriosis Age (years) 18 Proliferation 35.33 ± 2.701 0.968 17 Secretion 35.29 ± 3.037 BMI (kg/m 2 ) 18 Proliferation 23.71 (19.20–24.30) 0.843 17 Secretion 23.70 (21.60–24.50) GFR (ml/min/1.73 m) 18 Proliferation 114.444 ± 6.697 0.666 17 Secretion 115.294 ± 4.580 Serum creatinine (mg/dl) 18 Proliferation 0.65 (0.65–0.80) 1 17 Secretion 0.70 (0.60–0.70) Endometriosis Age (years) 19 Proliferation 35 (30–39) 0.055 19 Secretion 32 (30–39) BMI (kg/m 2 ) 19 Proliferation 23.63 (20.90–24.30) 0.174 19 Secretion 23.2 (18.40–24.40) Serum creatinine (mg/dl) 19 Proliferation 0.7 (0.60–0.80) 19 Secretion 0.6 (0.60–0.70) 0.068 GFR (ml/min/1.73 m) 19 Proliferation 113 (95–123) 0.109 19 Secretion 116 (109–123) Levels of cytokeratin-19 fragments (CYFRA 21-1) spot urine Table 2 presents the levels of cytokeratin-19 fragments (CYFRA 21-1) urine. It can be seen that the levels of cytokeratin-19 fragments (CYFRA 21-1) were significantly higher in the endometriosis group than in the non-endometriosis group (p < 0.05). The levels of cytokeratin-19 fragments (CYFRA 21-1) were significantly higher in the proliferative phase compared to the secretory phase in both the endometriosis and non-endometriosis groups. The AUC area at 80.7% (95% CI 70.3%–91.0%), p = 0.00, sensitivity of 76.3% and a specificity of 74.3% with the cutoff point of the cytokeratin-19 fragment (CYFRA 21-1) was 1.26 ng/ml ( Figure 1 ). Table 2. Levels of cytokeratin-19 fragments (CYFRA 21-1) spot urine based on endometriosis incidence and menstrual cycle phase. Endometriosis incidence and menstrual cycle phase n Cytokeratin-19 Level (ng/ml) median (min–max) p Non-endometriosis 35 0.741 (0.481–6.643) <0.001 Endometriosis 38 4.387 (0.380–15.779) Non-endometriosis Proliferation 18 1.12 (0.50–6.64) <0.001 Secretion 17 0.59 (0.48–1.60) Endometriosis Proliferative 19 9.57 (4.59–15.78) <0.001 Secretion 19 1.27 (0.38–4.18) Figure 1. ROC curve of CYFRA 21-1 urine in endometriosis without distinction of the menstrual cycle, in the proliferative, and secretory phase. In the analysis based on the cycle phase, it was found that the AUC in the proliferative phase was 97.1% (95% CI: 92.3%–100%). The considerable interpretation of the AUC for more than 90% was very good, with a p-value of <0.05 (p = 0.000). Meanwhile, the AUC in the secretory phase was 78.3% (95% CI: 61.8%–94.9%). The interpretation of the AUC is classified as moderate with a significance of p = 0.000. In the proliferative phase, the sensitivity and specificity were 89.5% and 88.9%, respectively, with a cutoff value of 5.024 ng/ml for the levels of cytokeratin-19 fragments (CYFRA 21-1). At the same time, in the secretory phase, the sensitivity and specificity were 78.9% and 82.4%, respectively, with a cutoff of 0.77 ng/ml. Cytokeratin-19 fragment (CYFRA 21-1) levels to creatinine (CYFRA/Cr) urine ratio Fluctuating random urine cytokeratin-19 fragment (CYFRA 21-1) levels need to be corrected with urine creatinine as a constant factor and generate a CYFRA 21-1 urine creatinine ratio or CYFRA/Cr. As presented in Table 3 , the cytokeratin-19 fragment (CYFRA 21-1) levels to creatinine (CYFRA/Cr) urine ratio was significantly higher in the endometriosis group than the non-endometriotic group (p < 0.05). Moreover, the cytokeratin-19 fragment (CYFRA 21-1) levels to creatinine (CYFRA/Cr) urine ratio was significantly higher in the proliferative phase compared with the secretory phase in both the endometriosis and non-endometriosis groups. Table 3. Cytokeratin-19 fragment (CYFRA 21-1) levels to creatinine (CYFRA/Cr) urine ratio based on endometriosis incidence and menstrual cycle phase. Endometriosis incidence and menstrual cycle phase level n Ratio CYFRA/Cr (ng/gr) median (min–max) p Non-endometriosis 35 757.971 (232.845 – 4.877.321) <0.001 Endometriosis 38 4592.474 (243.507 – 58423.827) Non-endometriosis Proliferative 18 1535.58 (757.97 – 4877.32) <0.001 Secretion 17 369.68 (232.85 – 745.30) Endometriosis Proliferative 19 15657.43 (3184.99 – 58423.83) <0.001 Secretion 19 1901.98 (243.51 – 12039.59) The AUC was 84.5% (95% CI: 75.5%–93.5%). The interpretation of an AUC of more than 80% is good, with p < 0.05 (p = 0.00). The sensitivity and specificity were 78.9% and 77.1%, respectively, with a cutoff value of 1,647.11 ng/gr in the cytokeratin-19 fragment (CYFRA 21-1) levels to creatinine (CYFRA/Cr) ratio ( Figure 2 ). Figure 2. ROC curve of CYFRA/Cr urine in endometriosis without distinction of the menstrual cycle, in the proliferative, and secretory phase. In the analysis based on the menstrual cycle phase, which was obtained based on the ROC curve in the proliferative phase, the AUC was 98.5% (95% CI: 95.7%–100%). The interpretation of an AUC of more than 90% was considered very good, with p < 0.05 (p = 0.015). The AUC in the secretory phase was 89.5% (95% CI: 78.5%–100%), and the interpretation of the AUC was classified as moderate with insignificant meaning p = 0.056. In the proliferative phase, the sensitivity and specificity were 94.7% and 94.4%, respectively, with a cutoff value of 3,547.99 ng/gr in the cytokeratin-19 fragment (CYFRA 21-1) level to creatinine (CYFRA/Cr) urine ratio. This result has the best sensitivity and specificity. At the same time, in the secretory phase, the sensitivity and specificity were 73.7% and 76.5%, respectively, with a cutoff value of 657.15 ng/gr. Discussion In this study, patient characteristics include age, BMI, and renal function based on serum creatinine values, and GFR values are important variables to avoid bias. Age included in inclusion criteria is in the range of 30–40 years due to the possibility that age will affect the production of cytokeratin-19 fragments (CYFRA 21-1). Renal function is also influenced by age ( National Kidney Foundation, 2002 ). Continuous decrease in GFR from a mean 123 mL/min/1.73 m 2 at age 20–29 years to a mean 65 mL/min/1.73 m 2 at age 80–89 years is a decline of about 10 mL/min per decade of age ( Delanaye & Rule, 2015 ). The presence of impaired renal function leads to the inability of the kidney to clear cytokeratin-19 fragments (CYFRA 21-1), resulting in increased levels of cytokeratin-19 fragments in the blood ( Rastel et al. , 1994 ). Other confounding factors identified were routine chest X-rays and routine urine examinations. Based on chest X-ray examination, it was within normal limits. Routine urine examination is a screening examination to rule out other diseases that affect the results, i.e., urinary tract infections, urinary tract stones, or urinary tract cancer. X-ray examination is important to avoid bias in the presence of other diseases that can increase the production of cytokeratin-19 fragments (CYFRA 21-1), i.e., lung cancer. Endometriosis is a disorder with various pathophysiologies. Hormonal, genetic, immunological, and oxidative stress factors are thought to be involved in the complex pathophysiology of endometriosis. This study found the high activity of oxidative stress in endometriotic tissue damage ( Chen et al. , 2020 ). The level of cytokeratin-19 fragment (CYFRA 21-1) spot urine in women with endometriosis was significantly higher than those without endometriosis. Cytokeratin-19 is expressed in glandular-type epithelium, one of which is the endometrial gland. Cytokeratin-19 normally occurs in the glandular epithelium both in the proliferative, secretory, and atrophic phases of the endometrium based on IHC examination. There is a more consistent expression in the functional layer, whereas the basal zone is usually focally stained. In the proliferative epithelium, cytokeratin-19 was seen in the basal and apical cytoplasm ( Stewart et al. , 2011 ). Ectopic endometrial tissue causes an immune hyper-reaction that affects the breakdown of cytokeratin-19 to CYFRA 21-1 ( Gjavotchanoff, 2015 ). Systemic release of cytokeratin-19 can occur through several mechanisms, including cellular apoptosis, abnormal mitosis, or release due to cell proliferation. Extracellular release occurs at the intermediate stage of epithelial cell apoptosis and during cell damage ( Fujita et al. , 2004 ). An increase in M2 activity was seen based on the pathophysiology of endometriosis through macrophage activity. Macrophages are supposed to act as classical phagocytes but, instead, increase their proliferation to form a neoplastic transformation. In this process, ectopic endometrial cells that bind to macrophages are thought to be damaged and release intracellular proteins ( Capobianco & Rovere-Querini, 2013 ). Cytokeratin-19 formed the smallest molecular weight of 40 kDa and consists of 400 amino acids encoded by the KRT 19 gene. The cytokeratin-19 fragment (CYFRA 21-1) formed soluble protein with a small molecular weight of 30 kDa (less than 19 kDa) as the molecule can pass through the glomerular filtration and be excreted in the urine ( Jose et al. , 2013 ). These results strengthen the findings of Tokushige et al. (2011) , who stressed urine protein is detected in endometriosis, which is then detected as CYFRA 21-1 through proteomic and western blotting techniques. At that time, Tokushige et al. (2011) could not determine how CYFRA 21-1 is released into the urine. Of note, the urine used in the previous study was urine that had been centrifuged. This study is also in line with the results obtained in the Gjavotchanoff (2015) , but the difference is in the correction of the creatinine factor. Cytokeratin-19 fragment (CYFRA 21-1) is a microprotein that breaks down easily at room temperature. In a study on the stability of the levels of cytokeratin-19 fragments (CYFRA 21-1) in urine at room temperature, it showed a decrease in levels associated with time ( Nisman et al. , 2002 ). Therefore, to maintain its stability after sample collection, it should be stored in a refrigerator. In this research, it was stored at −80°C. To maintain cold chain protein in the urine, the transportation process used an icebox. In a recent study in 2019 from a population in Korea, no significant difference was observed in levels of cytokeratin-19 fragments (CYFRA 21-1) between endometriosis and non-endometriosis. Meanwhile, the samples examined in this study were serum, and endometriosis controls were cases of non-endometrial ovarian tumors ( Cho & Kyung, 2019 ). A difference was observed in the levels of cytokeratin-19 fragments (CYFRA 21-1) between centrifuged and non-centrifuged urine, and the best results were obtained from uncentrifuged urine ( Gjavotchanoff, 2015 ; Nisman et al. , 2002 ). In this study, urine that was not centrifuged was used, although at the time of sample preparation the researchers prepared two preparations, i.e., centrifuged and non-centrifuged. During optimization, the best concentration was obtained from non-centrifuged urine. Inconsistency of results can also be caused by CYFRA 21-1 is a fluctuating protein so that spot urine test becomes inaccurate. If the levels of cytokeratin-19 fragments (CYFRA 21-1) were analyzed based on the phase of the menstrual cycle, the average levels of cytokeratin-19 fragments (CYFRA 21-1) obtained in the proliferative phase were significantly higher than the secretory phase in both endometriosis and non-endometriosis groups. This result is the same as that of Gjavotchanoff (2015) . There is a thickened functional stratum in the proliferative phase compared to the secretory phase. Based on the IHC examination, many cytokeratins were identified in the functional stratum ( Stewart et al. , 2011 ). Functional cells that undergo apoptosis or over-proliferation will release cytokeratin-19 into the system. Endometriotic functional tissue shows hyper-immunoreactivity to CYFRA 21-1 ( Gjavotchanoff, 2015 ). The best sensitivity and specificity values for cytokeratin-19 fragment (CYFRA 21-1) levels in spot urine were found in the proliferative phase where the sensitivity and specificity values were 89.5% and 88%, 9%, respectively, with a cutoff value of 5.024 ng/ml in the cytokeratin-19 fragment (CYFRA 21-1) level compared to the secretory phase and the overall value regardless of the cycle phase. This shows that the cycle phase is the predominant factor that must be considered because the cytokeratin-19 fragment (CYFRA 21-1) is a product of epithelial cells in which the intensity of epithelial cells in the endometrium and endometriotic cells is strongly influenced by cycle phase. However, the cytokeratin-19 fragments (CYFRA 21-1) spot urine test, unable to describe its level throughout the day so it must be compared with urine creatinine ( Gjavotchanoff, 2015 ). The presence of dilutional factors and circadian rhythms will affect the consistency of the examination. The standard in measuring urine protein is 24-h urine protein due to fluctuating protein excretion. However, the 24-h urine collection has many problems, so an alternative method can be used, specifically the urine protein and creatinine ratio recommended by the National Kidney Foundation and Kidney Disease Outcomes Global Improving (KDIGO) ( National Kidney Foundation, 2022 ). Chemical exposure assessment is a crucial aspect of public health and environmental monitoring. To determine the validity of a spot urine sample for this purpose, various parameters such as urinary creatinine concentrations, specific gravity, and osmolality are measured. These measurements help to adjust for dilution and report accurate analyte results. Among the methods used to account for dilution and report results, creatinine adjustment is the most widely accepted method. It involves dividing the analyte concentration (micrograms of analyte per liter of urine) by the creatinine concentration (grams of creatinine per liter of urine) and presenting the results as the weight of analyte per gram of creatinine (micrograms of analyte per gram of creatinine). This method is highly effective in ensuring accurate and reliable reporting of analyte levels in urine samples ( Barr et al. , 2005 ). The urine creatinine ratio was calculated as a constant level for the validity of the results of the levels of cytokeratin-19 fragments (CYFRA 21-1) spot urine test. Based on the analysis of the cytokeratin-19 fragment (CYFRA 21-1) to creatinine (CYFRA/Cr) urine ratio, it was found that the mean in the endometriosis group was significantly higher than in the non-endometriotic group. Based on the cycle phase, it was found that the average cytokeratin-19 fragment (CYFRA 21-1) to creatinine (CYFRA/Cr) urine ratio was significantly higher in the proliferative phase than the secretory phase in both the endometriosis and non-endometriosis groups. Compared with the levels of cytokeratin-19 fragments (CYFRA 21-1) in spot urine when can be seen differences in the results of the analysis in the secretory phase. Creatinine has been used as a reference value for calculating ratio in the dilution of the sample and matrix ( Gjavotchanoff, 2015 ). Other similar studies that calculated the ratio of cytokeratin-19 fragments (CYFRA 21-1) to creatinine (CYFRA/Cr) urine ratio have not been found, so it is difficult to compare this study with others. No research has been found that analyzes the cutoff value of cytokeratin-19 fragments (CYFRA 21-1) to creatinine (CYFRA/Cr) urine ratio in endometriosis. A study by Lessey et al. (2015) and Gjavohanoff (2015) have applied creatinine as a determinant; however, in explanation, the results of cytokeratin-19 fragments (CYFRA 21-1) to creatinine (CYFRA/Cr) urine ratio were not delivered. Based on recommendations from the National Kidney Foundation and Kidney Disease Outcomes Global Improving (KDIGO), the measurement of microprotein levels should be calculated based on urine creatinine levels as a stable matrix level in urine. This is because microproteins, which are one of the cytokeratin-19 fragments (CYFRA 21-1), are excreted in the urine at fluctuating levels, so it is not recommended to have a urine test during this time. For this reason, the measurement of cytokeratin-19 fragment (CYFRA 21-1) levels compared to urine creatinine as an alternative ( National Kidney Foundation, 2002 ). In this study, the best sensitivity and specificity were found in the cytokeratin-19 fragments (CYFRA 21-1) to creatinine (CYFRA/Cr) urine ratio measured in the proliferative phase, which is even better than the measurement of cytokeratin-19 fragment (CYFRA 21-1) spot urine. It was difficult to compare the finding of this cutoff value with other studies due to the limitations of the study, which divides sensitivity and specificity values based on the cycle phase. The other limitation is cycle phase determination, which was based on the patient’s menstrual history, not on the results of endometrial curettage. Accurate phasing should look at the histopathological features of the endometrium. CYFRA 21-1 spot urine levels are significantly higher in endometriosis than in non-endometriosis cases and are higher in the proliferative phase than in the secretory phase. The CYFRA/Cr ratio is also significantly higher in endometriosis than in non-endometriosis cases and higher in the proliferative than the secretory phase. Strengthening the accuracy of CYFRA 21-1 as a biomarker through correction of urine creatinine indicated by higher sensitivity and specificity of CYFRA/Cr than spot urine CYFRA, especially examined in the proliferative phase. It can be concluded that the CYFRA/Cr ratio can strengthen CYFRA 21-1 spot urine as a potential biomarker of endometriosis. Data availability Underlying data figshare: CYFRA 21-1 strengthening using Urine Creatinine, https://doi.org/10.6084/m9.figshare.24085353.v1 ( Saputra et al. , 2023 ). This project contains the raw, underlying data. Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0). Acknowledgements Thank you to the dean of the Faculty of Medicine, Universitas Riau, who has permitted me to research at the Lontar Biomedical Laboratory. Thank you is also conveyed to the director of Arifin Ahmad Hospital, Provinsi Riau, Indonesia, for the permission to collect samples. References Barr DB, Wilder LC, Caudill SP, et al. : Urinary creatinine concentrations in the U.S. population: Implications for urinary biologic monitoring measurements. Environ. Health Perspect. 2005; 113 (2): 192–200. PubMed Abstract | Publisher Full Text | Free Full Text Capobianco A, Rovere-Querini P: Endometriosis, a disease of the macrophage. Front. Immunol. 2013; 4 : 9. Chen PS, Chiu WT, Hsu PL, et al. : Pathophysiological implications of hypoxia in human diseases. J. Biomed. Sci. 2020; 27 (1): 63. PubMed Abstract | Publisher Full Text | Free Full Text Cho HY, Kyung MS: CYFRA 21-1 and placental growth factor as screening markers for endometriosis. Med. Sci. Monit. 2019; 25 : 1087–1092. PubMed Abstract | Publisher Full Text | Free Full Text de Almeida Filho DP , de Oliveira LJ , do Amaral VF : Accuracy of laparoscopy for assessing patients with endometriosis. Sao Paulo Med. J. 2008; 126 (6): 305–308. Publisher Full Text Delanaye P, Rule AD: Assessing Kidney Function. Chronic Renal Disease. 2015; pp. 31–42. Publisher Full Text Fassbender A, Burney RO, Dorien FO, et al. : Update on Biomarkers for the Detection of Endometriosis. Biomed. Res. Int. 2015; 2015 : 130854. Fujita J, Ohtsuki Y, Bandoh S, et al. : Elevation of cytokeratin 19 fragment (CYFRA 21-1) in serum of patients with radiation pneumonitis: possible marker of epithelial cell damage. Respir. Med. 2004; 98 (4): 294–300. PubMed Abstract | Publisher Full Text Gjavotchanoff R: CYFRA 21-1 in urine: A diagnostic marker for endometriosis? Int. J. Women’s Health. 2015; 7 : 205–211. Publisher Full Text Hogg S, Vyas S: Endometriosis. Obstetric Gynecology and Reproductive Medicine. United Kingdom: Elsevier Ltd; 2015. Jose J, Sunil PM, Nirmal M, et al. : CYFRA 21-1: An Overview. Oral Max. Pathol. J. 2013; 4 (2): 1–5. Kamińska J, Dymicka-Piekarska V, Tomaszewska J, et al. : Diagnostic utility of protein to creatinine ratio (P/C ratio) in spot urine sample within routine clinical practice. Crit. Rev. Clin. Lab. Sci. 2020; 57 (5): 345–364. PubMed Abstract | Publisher Full Text Kashiwabara K, Kishi K, Nakamura H, et al. : Mechanism of increased serum cytokeratin 19 fragment levels in patients with diabetic nephropathy as a model of chronic renal failure. Intern. Med. 1998; 37 (11): 917–921. PubMed Abstract | Publisher Full Text Lessey BA, Savaris RF, Ali S, et al. : Diagnostic accuracy of urinary cytokeratin 19 fragment for endometriosis. Reprod. Sci. 2015; 22 (5): 551–555. PubMed Abstract | Publisher Full Text | Free Full Text Liu E, Nisenblat V, Farquhar C, et al. : Urinary biomarkers for the non-invasive diagnosis of endometriosis. Cochrane Database Syst. Rev. 2015; 2015 (12): CD012019. Publisher Full Text National Kidney Foundation: Clinical practice guidlines for chronic kidney disease: Evaluation, classification and stratification. New York: National Kidney Foundation; 2002. Nisman B, Barak V, Shapiro A, et al. : Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma. Cancer. 2002; 94 (11): 2914–2922. PubMed Abstract | Publisher Full Text Nolen BM, Lomakin A, Marrangoni A, et al. : Urinary protein biomarkers in the early detection of lung cancer. Cancer Prev. Res. (Phila.). 2015; 8 (2): 111–119. PubMed Abstract | Publisher Full Text | Free Full Text Rastel D, Ramaioli A, Cornillie F, et al. : CYFRA 21-1, a sensitive and specific new tumour marker for squamous cell lung cancer. Report of the first European multicentre evaluation. Eur. J. Cancer. 1994; 30 (5): 601–606. Publisher Full Text Saputra N, Samsulhadi S, Hendarto H, et al. : CYFRA 21-1 strengthening using Urine Creatinine. [Dataset]. figshare. 2023. Publisher Full Text Schweizer J, Bowden PE, Coulombe PA, et al. : New consensus nomenclature for mammalian keratins. J. Cell Biol. 2006; 174 (2): 169–174. Publisher Full Text Stewart CJR, Crook ML, Lacey J, et al. : Cytokeratin 19 expression in normal endometrium and in low-grade endometrioid adenocarcinoma of the endometrium. Int. J. Gynecol. Pathol. 2011; 30 (5): 484–491. PubMed Abstract | Publisher Full Text Tokushige N, Markham R, Crossett B, et al. : Discovery of a novel biomarker in the urine in women with endometriosis. Fertil. Steril. 2011; 95 (1): 46–49. PubMed Abstract | Publisher Full Text Wykes CB, Clark TJ, Khan KS: Accuracy of laparoscopy in the diagnosis of endometriosis: A systematic quantitative review. BJOG. 2004; 111 (11): 1204–1212. PubMed Abstract | Publisher Full Text Comments on this article Comments (0) Version 2 VERSION 2 PUBLISHED 08 Jan 2024 ADD YOUR COMMENT Comment Author details Author details 1 Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Riau, Pekanbaru, Riau, Indonesia 2 Fertility and Reproductive Endocrinology Division, Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, Indonesia 3 Department of Public Health, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, Indonesia 4 Fertility and Endocrinology Division, Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Brawijaya, Malang, East Java, Indonesia Nicko Pisceski Kusika Saputra Roles: Conceptualization, Methodology, Validation, Writing – Original Draft Preparation Samsulhadi Samsulhadi Roles: Investigation, Software, Writing – Original Draft Preparation Hendy Hendarto Roles: Data Curation, Methodology, Writing – Original Draft Preparation Ashon Sa’adi Roles: Formal Analysis, Supervision, Writing – Original Draft Preparation Widodo J Pudjirahardjo Roles: Project Administration, Validation, Writing – Review & Editing I Wayan Arsana Roles: Methodology, Visualization, Writing – Review & Editing Relly Yanuari Roles: Formal Analysis, Supervision, Writing – Review & Editing Sri Ratna Dwiningsih Roles: Supervision, Validation, Writing – Review & Editing Competing interests No competing interests were disclosed. Grant information The author(s) declared that no grants were involved in supporting this work. Article Versions (2) version 2 Revised Published: 14 May 2025, 13:46 https://doi.org/10.12688/f1000research.135167.2 version 1 Published: 08 Jan 2024, 13:46 https://doi.org/10.12688/f1000research.135167.1 Copyright © 2024 Saputra NPK et al . This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Download Export To Sciwheel Bibtex EndNote ProCite Ref. Manager (RIS) Sente metrics Views Downloads F1000Research - - PubMed Central info_outline Data from PMC are received and updated monthly. - - Citations open_in_new 0 open_in_new 0 open_in_new SEE MORE DETAILS CITE how to cite this article Saputra NPK, Samsulhadi S, Hendarto H et al. Strengthening of CYFRA 21-1 using urine creatinine correction as potential endometriosis biomarker [version 1; peer review: 1 approved, 1 approved with reservations] . F1000Research 2024, 13 :46 ( https://doi.org/10.12688/f1000research.135167.1 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS track receive updates on this article Track an article to receive email alerts on any updates to this article. TRACK THIS ARTICLE Share Open Peer Review Current Reviewer Status: ? Key to Reviewer Statuses VIEW HIDE Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Version 1 VERSION 1 PUBLISHED 08 Jan 2024 Views 0 Cite How to cite this report: HEPOKUR CÖ. Reviewer Report For: Strengthening of CYFRA 21-1 using urine creatinine correction as potential endometriosis biomarker [version 1; peer review: 1 approved, 1 approved with reservations] . F1000Research 2024, 13 :46 ( https://doi.org/10.5256/f1000research.148270.r278758 ) The direct URL for this report is: https://f1000research.com/articles/13-46/v1#referee-response-278758 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 26 Jul 2024 Ceylan ÖZSOY HEPOKUR , Cumhuriyet University, Sivas, Turkey Approved VIEWS 0 https://doi.org/10.5256/f1000research.148270.r278758 The manuscript investigated whether CYFRA 21-1 is a biomarker in endometrosis patients. Three groups of patients were studied. The indexing of this article is acceptable with minor revision. 1. Direct abbreviation is used in the title (CYFRA 21-1), ... Continue reading READ ALL The manuscript investigated whether CYFRA 21-1 is a biomarker in endometrosis patients. Three groups of patients were studied. The indexing of this article is acceptable with minor revision. 1. Direct abbreviation is used in the title (CYFRA 21-1), it is recommended to write the open name to get easier citation. 2. It is recommended to express how the number of patients was chosen statistically (p power analysis). Is the work clearly and accurately presented and does it cite the current literature? Yes Is the study design appropriate and is the work technically sound? Yes Are sufficient details of methods and analysis provided to allow replication by others? Yes If applicable, is the statistical analysis and its interpretation appropriate? Yes Are all the source data underlying the results available to ensure full reproducibility? Yes Are the conclusions drawn adequately supported by the results? Yes Competing Interests: No competing interests were disclosed. Reviewer Expertise: obstetrics and gynaecology, Cancer, mİRNA, circRNA I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. Close READ LESS CITE CITE HOW TO CITE THIS REPORT HEPOKUR CÖ. Reviewer Report For: Strengthening of CYFRA 21-1 using urine creatinine correction as potential endometriosis biomarker [version 1; peer review: 1 approved, 1 approved with reservations] . F1000Research 2024, 13 :46 ( https://doi.org/10.5256/f1000research.148270.r278758 ) The direct URL for this report is: https://f1000research.com/articles/13-46/v1#referee-response-278758 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Author Response 07 Aug 2024 Hendy Hendarto , Fertility and Reproductive Endocrinology Division, Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia 07 Aug 2024 Author Response Dear Reviewer, Thank you for reviewing our work. We hope it will give a valuable insight for the readers. Thank you again. Best regards Competing Interests: No competing interests were disclosed. Dear Reviewer, Thank you for reviewing our work. We hope it will give a valuable insight for the readers. Thank you again. Best regards Dear Reviewer, Thank you for reviewing our work. We hope it will give a valuable insight for the readers. Thank you again. Best regards Competing Interests: No competing interests were disclosed. Close Report a concern Respond or Comment COMMENTS ON THIS REPORT Author Response 07 Aug 2024 Hendy Hendarto , Fertility and Reproductive Endocrinology Division, Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia 07 Aug 2024 Author Response Dear Reviewer, Thank you for reviewing our work. We hope it will give a valuable insight for the readers. Thank you again. Best regards Competing Interests: No competing interests were disclosed. Dear Reviewer, Thank you for reviewing our work. We hope it will give a valuable insight for the readers. Thank you again. Best regards Dear Reviewer, Thank you for reviewing our work. We hope it will give a valuable insight for the readers. Thank you again. Best regards Competing Interests: No competing interests were disclosed. Close Report a concern COMMENT ON THIS REPORT Views 0 Cite How to cite this report: Scheck SM. Reviewer Report For: Strengthening of CYFRA 21-1 using urine creatinine correction as potential endometriosis biomarker [version 1; peer review: 1 approved, 1 approved with reservations] . F1000Research 2024, 13 :46 ( https://doi.org/10.5256/f1000research.148270.r256952 ) The direct URL for this report is: https://f1000research.com/articles/13-46/v1#referee-response-256952 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 28 May 2024 Simon M Scheck , University of Otago, Dunedin, Otago, New Zealand Approved with Reservations VIEWS 0 https://doi.org/10.5256/f1000research.148270.r256952 This paper presents a larger valdiation of a previously suggested urinary marker to detect endometriosis. The novel approach of correcting using urinary creatinine is also tested and validated. The methodology is overall well done and the results ... Continue reading READ ALL This paper presents a larger valdiation of a previously suggested urinary marker to detect endometriosis. The novel approach of correcting using urinary creatinine is also tested and validated. The methodology is overall well done and the results are promising and warrant publication to spark further research. I would like to recommend a few changes. The source data provided is incomplete - the creatinine levels and the endometriosis diagnosis is not included. There is very little clinical data provided about the patients - why they were undergoing surgery, how endometriosis was diagnosed, and the extent/stage of disease needs to be provided - especially relevant for application as a biomarker. The discussion needs some work - is very long but doesn't actually discuss the key results or implications of these results in enough detail. Specific comments: Introduction Paragraph 1: Citing specificity and sensitivity for laparoscopy vs histopathology – this is a small study from 2008 and no longer relevant – all current international guidelines accept laparoscopy as the gold standard of diagnosis – cannot compare laparoscopic techniques of 2024 with those of 2008 Paragraph 3: “Cytokeratin-19 is found in simple and complex squamous epithelium” … “it is expressed in glandular-type epithelium” - squamous or glandular?? Paragraph 3: “increasing serum creatinine levels that cause decreasing in the level of cytokeratin-19 fragments (CYFRA 21-1) in the urine accompanied the increasing its serum level in urine” – serum level in the urine does not make sense… either serum or urine? Paragraph 3: “The mean levels of cytokeratin-19 fragments (CYFRA 21-1) were significantly higher in the proliferative phase than in the secretory phase” – it is unclear what this refers to… ? Serum, urine, endometrial samples? Patients with endometriosis? Normal women? I think it’s important to point out that the Tokushige study of n=16 did mass spectrometry looking at 917 different “protein spots” and found that CK-19 was different – they did not hypothesize that this particular protein would be relevant – and in the small sample size and the large number of multiple comparisons, it is possible this was due to chance and therefore further large scale studies (such as this one are important) Methods What was the indication for laparoscopy? Infertility or pain? Did the “non endometriosis” patients include those undergoing laparoscopy for other causes, such as tubal ligation, hysterectomy, ovarian cysts, etc… How thoroughly were those patients screened for endometriosis at laparoscopy? How was endometriosis diagnosed? Laparoscopy or histology? Was any staging information recorded? Do you have information about those with endometriomas or any other detail around the level of disease? (Small volume peritoneal disease may not be the same disease process as large volume nodular disease, endometriomas, etc.) “The AUC area at 80.7%” – AUC is not a percentage Could you present the data in table 2 and table 3 as box and whisker plots? Would be easier to interpret Discussion Start the discussion with a summary of the key findings: in the proliferative phase this study shows a very high sensitivity, specificity and AUC for CYFRA 21-1:creatinine ratio for detecting endometriosis - and make this the focus of the discussion The discussion has a lot of discussion around possible biological explanations for CYFRA 21 being excreted in urine, but not much discussion of the actual results I would like to see a more detailed discussion around: The results are highly significant in the proliferative phase without the creatinine correction – but they are improved with the creatinine correction – can you directly compare with and without creatinine correction and comment on this The results in the secretory phase are less significant both with and without the creatinine correction - is it possible that normal endometrium creates CYFRA 21 in the secretory phase, but that endometriosis tissue creates CYFRA 21 at all times, making it a more useful marker in the secretory phase? Is there any data to suggest what would happen for women on menstrual suppression (e.g. progesterone treatment) which is common in endometriosis patients? Is the work clearly and accurately presented and does it cite the current literature? Yes Is the study design appropriate and is the work technically sound? Yes Are sufficient details of methods and analysis provided to allow replication by others? Partly If applicable, is the statistical analysis and its interpretation appropriate? I cannot comment. A qualified statistician is required. Are all the source data underlying the results available to ensure full reproducibility? Partly Are the conclusions drawn adequately supported by the results? Yes Competing Interests: No competing interests were disclosed. Reviewer Expertise: I am a gynaecologist with experience in treating patients with endometriosis medically and surgically. I have limited lab experience, but have been involved with studies looking at cervical, vaginal and blood based biomarkers for endoemetriosis. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Scheck SM. Reviewer Report For: Strengthening of CYFRA 21-1 using urine creatinine correction as potential endometriosis biomarker [version 1; peer review: 1 approved, 1 approved with reservations] . F1000Research 2024, 13 :46 ( https://doi.org/10.5256/f1000research.148270.r256952 ) The direct URL for this report is: https://f1000research.com/articles/13-46/v1#referee-response-256952 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Author Response 14 May 2025 Hendy Hendarto , Fertility and Reproductive Endocrinology Division, Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia 14 May 2025 Author Response Dear Reviewer, Thank you for reviewing our work. We managed to revise the article according to your comments and suggestion. 1. We added more details on the creatinine level ... Continue reading Dear Reviewer, Thank you for reviewing our work. We managed to revise the article according to your comments and suggestion. 1. We added more details on the creatinine level assessment and endometriosis diagnosis method. 2. We added more details on the creatinine level assessment and endometriosis diagnosis method. The rASM data is not presented here as it will be published elsewhere.We added more details on the creatinine level assessment and endometriosis diagnosis method. The rASM data is not presented here as it will be published elsewhere. 3. We added more data in introduction. 4. Page 2 Line 42-43; 44-45 Cytokeratin-19 is expressed in 2 epithelia. Commonly on the simple and complex squamous cell epithelium. However, on endometrium, it is expressed by endometrial gland epithelium. 5. We revised the statement. The higher CYFRA 21-1 was in the urine of women with endometriosis. 6. We added the discussion of Tokushige’s publication as suggested. 7. We added more details on the sample selection. 8. We added more details on the endometriosis diagnosis method. 9. We revised the AUC value to decimal. 10. We added the summary of findings in the start of discussion. 11. We reduced the CYFRA-21 discussion as requested. 12. The result is significantly difference and we only have the result comparison between CYFRA and CYFRA with creatine treatment as we showed in the manuscript. 13. The growth of endometrial tissue in endometriosis causes an increase in the extent of functional tissue where the tissue contains cytokeratin-19 components. In endometriosis, progesterone resistance and increased estrogen occur which have an impact on increased cell proliferation and mitosis. Based on research by Kanaji et al 2011, the mechanism of cytokeratin release into extracellular is caused by apoptosis, disruption of cell membranes, cell division, surgical intervention, tissue necrosis caused by abnormal proliferation and this increases in the proliferation phase where the eutopic and ectopic endometrium experience abnormal proliferation caused by increased estrogen, where the nature of estrogen is proinflammatory and oncogenic. In contrast to the secretion phase where there is an increase in the hormone progesterone, Progesterone produced during the secretion phase can cause the endometrial mucosa not to be released, which means that endometriosis tissue also does not bleed and can develop into cysts. This explains why pregnancy, which increases progesterone levels, can reduce the development of endometriosis cysts. The nature of progesterone as an anti-inflammatory. Based on the Sperof book (2020) where stable endometrial conditions occur in estrogen and progesterone conditions. Where the endometrial wall is not fragile, there is no excessive proliferation. So it can be concluded that assessing endometriosis with urine cytokeratin 19 is best in the proliferation phase. Reference: Kanaji N, Bandoh S, Ishii T, Fujita J, Ishida T, Matsunaga T, Kubo A. Cytokeratins negatively regulate the invasive potential of lung cancer cell lines. Oncol Rep. 2011 Oct;26(4):763-8. doi: 10.3892/or.2011.1357. Epub 2011 Jun 23. PMID: 21701782. 14. As we do not have any data from subjects with menstrual suppression so we cannot comment in this moment. Those are the responses to your comments and suggestions. We also upload the point-to-point responses. Thank you for your concern. Best regards Dear Reviewer, Thank you for reviewing our work. We managed to revise the article according to your comments and suggestion. 1. We added more details on the creatinine level assessment and endometriosis diagnosis method. 2. We added more details on the creatinine level assessment and endometriosis diagnosis method. The rASM data is not presented here as it will be published elsewhere.We added more details on the creatinine level assessment and endometriosis diagnosis method. The rASM data is not presented here as it will be published elsewhere. 3. We added more data in introduction. 4. Page 2 Line 42-43; 44-45 Cytokeratin-19 is expressed in 2 epithelia. Commonly on the simple and complex squamous cell epithelium. However, on endometrium, it is expressed by endometrial gland epithelium. 5. We revised the statement. The higher CYFRA 21-1 was in the urine of women with endometriosis. 6. We added the discussion of Tokushige’s publication as suggested. 7. We added more details on the sample selection. 8. We added more details on the endometriosis diagnosis method. 9. We revised the AUC value to decimal. 10. We added the summary of findings in the start of discussion. 11. We reduced the CYFRA-21 discussion as requested. 12. The result is significantly difference and we only have the result comparison between CYFRA and CYFRA with creatine treatment as we showed in the manuscript. 13. The growth of endometrial tissue in endometriosis causes an increase in the extent of functional tissue where the tissue contains cytokeratin-19 components. In endometriosis, progesterone resistance and increased estrogen occur which have an impact on increased cell proliferation and mitosis. Based on research by Kanaji et al 2011, the mechanism of cytokeratin release into extracellular is caused by apoptosis, disruption of cell membranes, cell division, surgical intervention, tissue necrosis caused by abnormal proliferation and this increases in the proliferation phase where the eutopic and ectopic endometrium experience abnormal proliferation caused by increased estrogen, where the nature of estrogen is proinflammatory and oncogenic. In contrast to the secretion phase where there is an increase in the hormone progesterone, Progesterone produced during the secretion phase can cause the endometrial mucosa not to be released, which means that endometriosis tissue also does not bleed and can develop into cysts. This explains why pregnancy, which increases progesterone levels, can reduce the development of endometriosis cysts. The nature of progesterone as an anti-inflammatory. Based on the Sperof book (2020) where stable endometrial conditions occur in estrogen and progesterone conditions. Where the endometrial wall is not fragile, there is no excessive proliferation. So it can be concluded that assessing endometriosis with urine cytokeratin 19 is best in the proliferation phase. Reference: Kanaji N, Bandoh S, Ishii T, Fujita J, Ishida T, Matsunaga T, Kubo A. Cytokeratins negatively regulate the invasive potential of lung cancer cell lines. Oncol Rep. 2011 Oct;26(4):763-8. doi: 10.3892/or.2011.1357. Epub 2011 Jun 23. PMID: 21701782. 14. As we do not have any data from subjects with menstrual suppression so we cannot comment in this moment. Those are the responses to your comments and suggestions. We also upload the point-to-point responses. Thank you for your concern. Best regards Competing Interests: No competing interests were disclosed. Close Report a concern Respond or Comment COMMENTS ON THIS REPORT Author Response 14 May 2025 Hendy Hendarto , Fertility and Reproductive Endocrinology Division, Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia 14 May 2025 Author Response Dear Reviewer, Thank you for reviewing our work. We managed to revise the article according to your comments and suggestion. 1. We added more details on the creatinine level ... Continue reading Dear Reviewer, Thank you for reviewing our work. We managed to revise the article according to your comments and suggestion. 1. We added more details on the creatinine level assessment and endometriosis diagnosis method. 2. We added more details on the creatinine level assessment and endometriosis diagnosis method. The rASM data is not presented here as it will be published elsewhere.We added more details on the creatinine level assessment and endometriosis diagnosis method. The rASM data is not presented here as it will be published elsewhere. 3. We added more data in introduction. 4. Page 2 Line 42-43; 44-45 Cytokeratin-19 is expressed in 2 epithelia. Commonly on the simple and complex squamous cell epithelium. However, on endometrium, it is expressed by endometrial gland epithelium. 5. We revised the statement. The higher CYFRA 21-1 was in the urine of women with endometriosis. 6. We added the discussion of Tokushige’s publication as suggested. 7. We added more details on the sample selection. 8. We added more details on the endometriosis diagnosis method. 9. We revised the AUC value to decimal. 10. We added the summary of findings in the start of discussion. 11. We reduced the CYFRA-21 discussion as requested. 12. The result is significantly difference and we only have the result comparison between CYFRA and CYFRA with creatine treatment as we showed in the manuscript. 13. The growth of endometrial tissue in endometriosis causes an increase in the extent of functional tissue where the tissue contains cytokeratin-19 components. In endometriosis, progesterone resistance and increased estrogen occur which have an impact on increased cell proliferation and mitosis. Based on research by Kanaji et al 2011, the mechanism of cytokeratin release into extracellular is caused by apoptosis, disruption of cell membranes, cell division, surgical intervention, tissue necrosis caused by abnormal proliferation and this increases in the proliferation phase where the eutopic and ectopic endometrium experience abnormal proliferation caused by increased estrogen, where the nature of estrogen is proinflammatory and oncogenic. In contrast to the secretion phase where there is an increase in the hormone progesterone, Progesterone produced during the secretion phase can cause the endometrial mucosa not to be released, which means that endometriosis tissue also does not bleed and can develop into cysts. This explains why pregnancy, which increases progesterone levels, can reduce the development of endometriosis cysts. The nature of progesterone as an anti-inflammatory. Based on the Sperof book (2020) where stable endometrial conditions occur in estrogen and progesterone conditions. Where the endometrial wall is not fragile, there is no excessive proliferation. So it can be concluded that assessing endometriosis with urine cytokeratin 19 is best in the proliferation phase. Reference: Kanaji N, Bandoh S, Ishii T, Fujita J, Ishida T, Matsunaga T, Kubo A. Cytokeratins negatively regulate the invasive potential of lung cancer cell lines. Oncol Rep. 2011 Oct;26(4):763-8. doi: 10.3892/or.2011.1357. Epub 2011 Jun 23. PMID: 21701782. 14. As we do not have any data from subjects with menstrual suppression so we cannot comment in this moment. Those are the responses to your comments and suggestions. We also upload the point-to-point responses. Thank you for your concern. Best regards Dear Reviewer, Thank you for reviewing our work. We managed to revise the article according to your comments and suggestion. 1. We added more details on the creatinine level assessment and endometriosis diagnosis method. 2. We added more details on the creatinine level assessment and endometriosis diagnosis method. The rASM data is not presented here as it will be published elsewhere.We added more details on the creatinine level assessment and endometriosis diagnosis method. The rASM data is not presented here as it will be published elsewhere. 3. We added more data in introduction. 4. Page 2 Line 42-43; 44-45 Cytokeratin-19 is expressed in 2 epithelia. Commonly on the simple and complex squamous cell epithelium. However, on endometrium, it is expressed by endometrial gland epithelium. 5. We revised the statement. The higher CYFRA 21-1 was in the urine of women with endometriosis. 6. We added the discussion of Tokushige’s publication as suggested. 7. We added more details on the sample selection. 8. We added more details on the endometriosis diagnosis method. 9. We revised the AUC value to decimal. 10. We added the summary of findings in the start of discussion. 11. We reduced the CYFRA-21 discussion as requested. 12. The result is significantly difference and we only have the result comparison between CYFRA and CYFRA with creatine treatment as we showed in the manuscript. 13. The growth of endometrial tissue in endometriosis causes an increase in the extent of functional tissue where the tissue contains cytokeratin-19 components. In endometriosis, progesterone resistance and increased estrogen occur which have an impact on increased cell proliferation and mitosis. Based on research by Kanaji et al 2011, the mechanism of cytokeratin release into extracellular is caused by apoptosis, disruption of cell membranes, cell division, surgical intervention, tissue necrosis caused by abnormal proliferation and this increases in the proliferation phase where the eutopic and ectopic endometrium experience abnormal proliferation caused by increased estrogen, where the nature of estrogen is proinflammatory and oncogenic. In contrast to the secretion phase where there is an increase in the hormone progesterone, Progesterone produced during the secretion phase can cause the endometrial mucosa not to be released, which means that endometriosis tissue also does not bleed and can develop into cysts. This explains why pregnancy, which increases progesterone levels, can reduce the development of endometriosis cysts. The nature of progesterone as an anti-inflammatory. Based on the Sperof book (2020) where stable endometrial conditions occur in estrogen and progesterone conditions. Where the endometrial wall is not fragile, there is no excessive proliferation. So it can be concluded that assessing endometriosis with urine cytokeratin 19 is best in the proliferation phase. Reference: Kanaji N, Bandoh S, Ishii T, Fujita J, Ishida T, Matsunaga T, Kubo A. Cytokeratins negatively regulate the invasive potential of lung cancer cell lines. Oncol Rep. 2011 Oct;26(4):763-8. doi: 10.3892/or.2011.1357. Epub 2011 Jun 23. PMID: 21701782. 14. As we do not have any data from subjects with menstrual suppression so we cannot comment in this moment. Those are the responses to your comments and suggestions. We also upload the point-to-point responses. Thank you for your concern. Best regards Competing Interests: No competing interests were disclosed. Close Report a concern COMMENT ON THIS REPORT Comments on this article Comments (0) Version 2 VERSION 2 PUBLISHED 08 Jan 2024 ADD YOUR COMMENT Comment keyboard_arrow_left keyboard_arrow_right Open Peer Review Reviewer Status info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Reviewer Reports Invited Reviewers 1 2 3 Version 2 (revision) 14 May 25 read Version 1 08 Jan 24 read read Simon M Scheck , University of Otago, Dunedin, New Zealand Ceylan ÖZSOY HEPOKUR , Cumhuriyet University, Sivas, Turkey Daniel Vaiman , Université de Paris, Paris, France Comments on this article All Comments (0) Add a comment Sign up for content alerts Sign Up You are now signed up to receive this alert Browse by related subjects keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2025 Vaiman D. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 03 Jun 2025 | for Version 2 Daniel Vaiman , Université de Paris, Paris, France 0 Views copyright © 2025 Vaiman D. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (1) Approved info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Endometriosis is a disease with a long period of absence of diagnostic (estimated at 7 years on average and at least). Having molecular markers proving the disease is thus an important issue for patients throughout the world. The study is based upon the urinary measure of the ratio CYFRA 21-1 / creatinine as a biomarker. CYFRA 21-1 is a fragment of cytokeratin n19 The rationale is the following: the protein was identified initially in a small sample of 16 patients in urine, with reported variations according to the period of the cycle. Variations observed impede the use of the molecule as a markler, but here, the authors proposed to correct the level by the creatine level inside the urine. In the study 73 patients were included (38 endometriosis and 35 controls, each category being divided almost equally between proliferative and secretive phases). The result reveals excellent ROC curves, especially in the proliferative phase, and this is largely improved when the ratio is used, assuming an AUC of 0.99 and 0.95 in proliferative and secretive phases, respectively. This is an extremely nice result using a single marker. Discussion might remain to be written about the capability of this test to distinguish the patients at early stages of the disease, maybe before the symptoms reach high levels, or are very well established. It should be emphasized the care for the quality of the definitions of the patients, which while the number is relatively limited appears as a unusual effort in the literature in the field. Is the work clearly and accurately presented and does it cite the current literature? Yes Is the study design appropriate and is the work technically sound? Yes Are sufficient details of methods and analysis provided to allow replication by others? Yes If applicable, is the statistical analysis and its interpretation appropriate? Yes Are all the source data underlying the results available to ensure full reproducibility? Yes Are the conclusions drawn adequately supported by the results? Yes Competing Interests No competing interests were disclosed. Reviewer Expertise Reproductive Biology I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. reply Respond to this report Responses (1) Author Response 11 Sep 2025 Hendy Hendarto, Fertility and Reproductive Endocrinology Division, Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia Dear Reviewer, Thank you for reviewing our work. We hope it will give a valuable insight for the readers. Thank you again. Best regards View more View less Competing Interests No competing interests were disclosed. reply Respond Report a concern Vaiman D. Peer Review Report For: Strengthening of CYFRA 21-1 using urine creatinine correction as potential endometriosis biomarker [version 1; peer review: 1 approved, 1 approved with reservations] . F1000Research 2024, 13 :46 ( https://doi.org/10.5256/f1000research.170068.r387639) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://f1000research.com/articles/13-46/v2#referee-response-387639 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2024 HEPOKUR C. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 26 Jul 2024 | for Version 1 Ceylan ÖZSOY HEPOKUR , Cumhuriyet University, Sivas, Turkey 0 Views copyright © 2024 HEPOKUR C. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (1) Approved info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions The manuscript investigated whether CYFRA 21-1 is a biomarker in endometrosis patients. Three groups of patients were studied. The indexing of this article is acceptable with minor revision. 1. Direct abbreviation is used in the title (CYFRA 21-1), it is recommended to write the open name to get easier citation. 2. It is recommended to express how the number of patients was chosen statistically (p power analysis). Is the work clearly and accurately presented and does it cite the current literature? Yes Is the study design appropriate and is the work technically sound? Yes Are sufficient details of methods and analysis provided to allow replication by others? Yes If applicable, is the statistical analysis and its interpretation appropriate? Yes Are all the source data underlying the results available to ensure full reproducibility? Yes Are the conclusions drawn adequately supported by the results? Yes Competing Interests No competing interests were disclosed. Reviewer Expertise obstetrics and gynaecology, Cancer, mİRNA, circRNA I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. reply Respond to this report Responses (1) Author Response 07 Aug 2024 Hendy Hendarto, Fertility and Reproductive Endocrinology Division, Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia Dear Reviewer, Thank you for reviewing our work. We hope it will give a valuable insight for the readers. Thank you again. Best regards View more View less Competing Interests No competing interests were disclosed. reply Respond Report a concern HEPOKUR CÖ. Peer Review Report For: Strengthening of CYFRA 21-1 using urine creatinine correction as potential endometriosis biomarker [version 1; peer review: 1 approved, 1 approved with reservations] . F1000Research 2024, 13 :46 ( https://doi.org/10.5256/f1000research.148270.r278758) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://f1000research.com/articles/13-46/v1#referee-response-278758 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2024 Scheck S. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 28 May 2024 | for Version 1 Simon M Scheck , University of Otago, Dunedin, Otago, New Zealand 0 Views copyright © 2024 Scheck S. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (1) Approved With Reservations info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions This paper presents a larger valdiation of a previously suggested urinary marker to detect endometriosis. The novel approach of correcting using urinary creatinine is also tested and validated. The methodology is overall well done and the results are promising and warrant publication to spark further research. I would like to recommend a few changes. The source data provided is incomplete - the creatinine levels and the endometriosis diagnosis is not included. There is very little clinical data provided about the patients - why they were undergoing surgery, how endometriosis was diagnosed, and the extent/stage of disease needs to be provided - especially relevant for application as a biomarker. The discussion needs some work - is very long but doesn't actually discuss the key results or implications of these results in enough detail. Specific comments: Introduction Paragraph 1: Citing specificity and sensitivity for laparoscopy vs histopathology – this is a small study from 2008 and no longer relevant – all current international guidelines accept laparoscopy as the gold standard of diagnosis – cannot compare laparoscopic techniques of 2024 with those of 2008 Paragraph 3: “Cytokeratin-19 is found in simple and complex squamous epithelium” … “it is expressed in glandular-type epithelium” - squamous or glandular?? Paragraph 3: “increasing serum creatinine levels that cause decreasing in the level of cytokeratin-19 fragments (CYFRA 21-1) in the urine accompanied the increasing its serum level in urine” – serum level in the urine does not make sense… either serum or urine? Paragraph 3: “The mean levels of cytokeratin-19 fragments (CYFRA 21-1) were significantly higher in the proliferative phase than in the secretory phase” – it is unclear what this refers to… ? Serum, urine, endometrial samples? Patients with endometriosis? Normal women? I think it’s important to point out that the Tokushige study of n=16 did mass spectrometry looking at 917 different “protein spots” and found that CK-19 was different – they did not hypothesize that this particular protein would be relevant – and in the small sample size and the large number of multiple comparisons, it is possible this was due to chance and therefore further large scale studies (such as this one are important) Methods What was the indication for laparoscopy? Infertility or pain? Did the “non endometriosis” patients include those undergoing laparoscopy for other causes, such as tubal ligation, hysterectomy, ovarian cysts, etc… How thoroughly were those patients screened for endometriosis at laparoscopy? How was endometriosis diagnosed? Laparoscopy or histology? Was any staging information recorded? Do you have information about those with endometriomas or any other detail around the level of disease? (Small volume peritoneal disease may not be the same disease process as large volume nodular disease, endometriomas, etc.) “The AUC area at 80.7%” – AUC is not a percentage Could you present the data in table 2 and table 3 as box and whisker plots? Would be easier to interpret Discussion Start the discussion with a summary of the key findings: in the proliferative phase this study shows a very high sensitivity, specificity and AUC for CYFRA 21-1:creatinine ratio for detecting endometriosis - and make this the focus of the discussion The discussion has a lot of discussion around possible biological explanations for CYFRA 21 being excreted in urine, but not much discussion of the actual results I would like to see a more detailed discussion around: The results are highly significant in the proliferative phase without the creatinine correction – but they are improved with the creatinine correction – can you directly compare with and without creatinine correction and comment on this The results in the secretory phase are less significant both with and without the creatinine correction - is it possible that normal endometrium creates CYFRA 21 in the secretory phase, but that endometriosis tissue creates CYFRA 21 at all times, making it a more useful marker in the secretory phase? Is there any data to suggest what would happen for women on menstrual suppression (e.g. progesterone treatment) which is common in endometriosis patients? Is the work clearly and accurately presented and does it cite the current literature? Yes Is the study design appropriate and is the work technically sound? Yes Are sufficient details of methods and analysis provided to allow replication by others? Partly If applicable, is the statistical analysis and its interpretation appropriate? I cannot comment. A qualified statistician is required. Are all the source data underlying the results available to ensure full reproducibility? Partly Are the conclusions drawn adequately supported by the results? Yes Competing Interests No competing interests were disclosed. Reviewer Expertise I am a gynaecologist with experience in treating patients with endometriosis medically and surgically. I have limited lab experience, but have been involved with studies looking at cervical, vaginal and blood based biomarkers for endoemetriosis. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. reply Respond to this report Responses (1) Author Response 14 May 2025 Hendy Hendarto, Fertility and Reproductive Endocrinology Division, Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia Dear Reviewer, Thank you for reviewing our work. We managed to revise the article according to your comments and suggestion. 1. We added more details on the creatinine level assessment and endometriosis diagnosis method. 2. We added more details on the creatinine level assessment and endometriosis diagnosis method. The rASM data is not presented here as it will be published elsewhere.We added more details on the creatinine level assessment and endometriosis diagnosis method. The rASM data is not presented here as it will be published elsewhere. 3. We added more data in introduction. 4. Page 2 Line 42-43; 44-45 Cytokeratin-19 is expressed in 2 epithelia. Commonly on the simple and complex squamous cell epithelium. However, on endometrium, it is expressed by endometrial gland epithelium. 5. We revised the statement. The higher CYFRA 21-1 was in the urine of women with endometriosis. 6. We added the discussion of Tokushige’s publication as suggested. 7. We added more details on the sample selection. 8. We added more details on the endometriosis diagnosis method. 9. We revised the AUC value to decimal. 10. We added the summary of findings in the start of discussion. 11. We reduced the CYFRA-21 discussion as requested. 12. The result is significantly difference and we only have the result comparison between CYFRA and CYFRA with creatine treatment as we showed in the manuscript. 13. The growth of endometrial tissue in endometriosis causes an increase in the extent of functional tissue where the tissue contains cytokeratin-19 components. In endometriosis, progesterone resistance and increased estrogen occur which have an impact on increased cell proliferation and mitosis. Based on research by Kanaji et al 2011, the mechanism of cytokeratin release into extracellular is caused by apoptosis, disruption of cell membranes, cell division, surgical intervention, tissue necrosis caused by abnormal proliferation and this increases in the proliferation phase where the eutopic and ectopic endometrium experience abnormal proliferation caused by increased estrogen, where the nature of estrogen is proinflammatory and oncogenic. In contrast to the secretion phase where there is an increase in the hormone progesterone, Progesterone produced during the secretion phase can cause the endometrial mucosa not to be released, which means that endometriosis tissue also does not bleed and can develop into cysts. This explains why pregnancy, which increases progesterone levels, can reduce the development of endometriosis cysts. The nature of progesterone as an anti-inflammatory. Based on the Sperof book (2020) where stable endometrial conditions occur in estrogen and progesterone conditions. Where the endometrial wall is not fragile, there is no excessive proliferation. So it can be concluded that assessing endometriosis with urine cytokeratin 19 is best in the proliferation phase. Reference: Kanaji N, Bandoh S, Ishii T, Fujita J, Ishida T, Matsunaga T, Kubo A. Cytokeratins negatively regulate the invasive potential of lung cancer cell lines. Oncol Rep. 2011 Oct;26(4):763-8. doi: 10.3892/or.2011.1357. Epub 2011 Jun 23. PMID: 21701782. 14. As we do not have any data from subjects with menstrual suppression so we cannot comment in this moment. Those are the responses to your comments and suggestions. We also upload the point-to-point responses. Thank you for your concern. Best regards View more View less Competing Interests No competing interests were disclosed. reply Respond Report a concern Scheck SM. Peer Review Report For: Strengthening of CYFRA 21-1 using urine creatinine correction as potential endometriosis biomarker [version 1; peer review: 1 approved, 1 approved with reservations] . F1000Research 2024, 13 :46 ( https://doi.org/10.5256/f1000research.148270.r256952) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://f1000research.com/articles/13-46/v1#referee-response-256952 Alongside their report, reviewers assign a status to the article: Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions Adjust parameters to alter display View on desktop for interactive features Includes Interactive Elements View on desktop for interactive features Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Stay Updated Sign up for content alerts and receive a weekly or monthly email with all newly published articles Register with F1000Research Already registered? Sign in Not now, thanks close PLEASE NOTE If you are an AUTHOR of this article, please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a “User Comment”. If you are a REVIEWER of this article, please check that you have signed in with the account associated with this article and then go to your account to submit your report, please do not post your review here. If you do not have access to your original account, please contact us . All commenters must hold a formal affiliation as per our Policies . The information that you give us will be displayed next to your comment. User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the User Comment Terms and Conditions . Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available. I accept the User Comment Terms and Conditions Please confirm that you accept the User Comment Terms and Conditions. Affiliation ✕ refresh Please enter your institution. Note: To add your institution or organisation, start typing the name and then select the correct name from the list. Where applicable, the name will appear in both the original language and in English. Do not paste in the name. If the name does not appear in the drop-down list, we will display the information you have entered. ✕ refresh Country/Region * USA UK Canada China France Germany Afghanistan Aland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory British Virgin Islands Brunei Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Cook Islands Costa Rica Cote d'Ivoire Croatia Cuba Cyprus Czech Republic Democratic Republic of the Congo Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Federated States of Micronesia Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and Mcdonald Islands Holy See (Vatican City State) Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo (Serbia and Montenegro) Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macao Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Minor Outlying Islands of the United States Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island North Korea North Macedonia Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Romania Russian Federation Rwanda Saint Helena Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Is South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand The Gambia The Netherlands Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu UK USA Uganda Ukraine United Arab Emirates United States Virgin Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam Wallis and Futuna West Bank and Gaza Strip Western Sahara Yemen Zambia Zimbabwe Please select your country/region. You must enter a comment. Competing Interests Please disclose any competing interests that might be construed to influence your judgment of the article's or peer review report's validity or importance. Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Please state your competing interests The comment has been saved. An error has occurred. Please try again. Cancel Post var lTitle = "Strengthening of CYFRA 21-1 using urine creatinine...".replace("'", ''); var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/13-46/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by '); var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/13-46/v1&title=" + encodeURIComponent(lTitle); var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/13-46/v1" + "&title=" + encodeURIComponent(lTitle); linkedInUrl += encodeURIComponent('Saputra NPK et al.'); var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; var addthis_config = { ui_offset_top: offsetTop, services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_custom : [ { name: "LinkedIn", url: linkedInUrl, icon:"/img/icon/at_linkedin.svg" }, { name: "Mendeley", url: "http://www.mendeley.com/import/?url=https://f1000research.com/articles/13-46/v1/mendeley", icon:"/img/icon/at_mendeley.svg" }, { name: "Reddit", url: redditUrl, icon:"/img/icon/at_reddit.svg" }, ] }; var addthis_share = { url: "https://f1000research.com/articles/13-46", templates : { twitter : "Strengthening of CYFRA 21-1 using urine creatinine correction.... Saputra NPK et al., published by " + "@F1000Research" + ", https://f1000research.com/articles/13-46/v1" } }; if (typeof(addthis) != "undefined"){ addthis.addEventListener('addthis.ready', checkCount); addthis.addEventListener('addthis.menu.share', checkCount); } $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter); $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url); $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url); $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url); $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url); function checkCount(){ setTimeout(function(){ $(".addthis_button_expanded").each(function(){ var count = $(this).text(); if (count !== "" && count != "0") $(this).removeClass("is-hidden"); else $(this).addClass("is-hidden"); }); }, 1000); } close How to cite this report {{reportCitation}} Cancel Copy Citation Details $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');}); $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');}); $.get("/articles/acj/135167/148270") new F1000.Clipboard(); new F1000.ThesaurusTermsDisplay("articles", "article", "148270"); $(document).ready(function() { $( "#frame1" ).on('load', function() { var mydiv = $(this).contents().find("div"); var h = mydiv.height(); console.log(h) }); var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"), titleLivingFigure = tooltipLivingFigure.attr("title"); tooltipLivingFigure.simpletip({ fixed: true, position: ["-115", "30"], baseClass: 'small-tooltip', content:titleLivingFigure + " " }); tooltipLivingFigure.removeAttr("title"); $("body").on("click", ".cite-living-figure", function(e) { e.preventDefault(); var ref = $(this).attr("data-ref"); $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200); }); $("body").on("click", ".close-cite-living-figure", function(e) { e.preventDefault(); $(this).closest(".popup-window-wrapper").fadeOut(200); }); $(document).on("mouseup", function(e) { var metricsContainer = $(".article-metrics-popover-wrapper"); if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) { $(".article-metrics-close-button").click(); } }); var articleId = $('#articleId').val(); if($("#main-article-count-box").attachArticleMetrics) { $("#main-article-count-box").attachArticleMetrics(articleId, { articleMetricsView: true }); } }); var figshareWidget = $(".new_figshare_widget"); if (figshareWidget.length > 0) { window.figshare.load("f1000", function(Widget) { // Select a tag/tags defined in your page. In this tag we will place the widget. _.map(figshareWidget, function(el){ var widget = new Widget({ articleId: $(el).attr("figshare_articleId") //height:300 // this is the height of the viewer part. [Default: 550] }); widget.initialize(); // initialize the widget widget.mount(el); // mount it in a tag that's on your page // this will save the widget on the global scope for later use from // your JS scripts. This line is optional. //window.widget = widget; }); }); } close Error Close Add Reset F1000.MICROSERVICES.AFFILIATION = ''; $(document).ready(function () { $('.js-affiliations-form').each((index, form) => { new AffiliationForm({ formId: form.id, institutionErrorSelector: '.comment-enter-institution', departmentErrorSelector: '.comment-enter-department', placeSelector: '.js-add-comment-place', stateSelector: '.js-add-comment-state', zipCodeSelector: '.js-add-comment-zipcode', countrySelector: '.js-add-comment-country', countryErrorSelector: '.comment-enter-country', }); }); }); $(document).ready(function () { var reportIds = { "295168": 0, "295169": 0, "295170": 0, "249891": 0, "249890": 0, "249895": 0, "249894": 0, "249893": 0, "249892": 0, "249899": 0, "266924": 0, "249898": 0, "266925": 0, "249897": 0, "266926": 0, "249896": 0, "266927": 0, "256947": 0, "266932": 0, "387637": 0, "256946": 0, "266933": 0, "387636": 0, "256945": 0, "387639": 6, "387638": 0, "256951": 0, "266928": 0, "256950": 0, "266929": 0, "256949": 0, "266930": 0, "387635": 0, "256948": 0, "266931": 0, "256954": 0, "384828": 0, "256953": 0, "256952": 39, "387641": 0, "387640": 0, "387643": 0, "384827": 0, "387642": 0, "244291": 0, "244295": 0, "244294": 0, "244293": 0, "244292": 0, "244299": 0, "244298": 0, "244297": 0, "244296": 0, "244300": 0, "278750": 0, "385503": 0, "278751": 0, "278756": 0, "385509": 0, "278757": 0, "385508": 0, "278758": 26, "278759": 0, "385510": 0, "278752": 0, "385505": 0, "278753": 0, "385504": 0, "278754": 0, "385507": 0, "278755": 0, "385506": 0, "295165": 0, "295166": 0, "295167": 0, }; $(".referee-response-container,.js-referee-report").each(function(index, el) { var reportId = $(el).attr("data-reportid"), reportCount = reportIds[reportId] || 0; $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount); }); var uuidInput = $("#article_uuid"), oldUUId = uuidInput.val(), newUUId = "0e7a0276-9d9f-48fb-80e9-379c17c9c417"; uuidInput.val(newUUId); $("a[href*='article_uuid=']").each(function(index, el) { var newHref = $(el).attr("href").replace(oldUUId, newUUId); $(el).attr("href", newHref); }); }); An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing. Browse Gateways Collections How it Works Contact For Developers Cookie Notice Privacy Notice RSS Submit Your Research Follow us © 2012-2026 F1000 Research Ltd. ISSN 2046-1402 | Legal | Partner of Research4Life • CrossRef • ORCID • FAIRSharing R.templateTests.simpleTemplate = R.template(' $text $text $text $text $text '); R.templateTests.runTests(); var F1000platform = new F1000.Platform({ name: "f1000research", displayName: "F1000Research", hostName: "f1000research.com", id: "1", editorialEmail: "[email protected]", infoEmail: "[email protected]", usePmcStats: true }); $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');}); // $(function(){R.ui.dropdowns('.dropdown-for-referees');}); $(document).ready(function () { if ($(".cookie-warning").is(":visible")) { $(".sticky").css("margin-bottom", "35px"); $(".devices").addClass("devices-and-cookie-warning"); } $(".cookie-warning .close-button").click(function (e) { $(".devices").removeClass("devices-and-cookie-warning"); $(".sticky").css("margin-bottom", "0"); }); $("#tweeter-feed .tweet-message").each(function (i, message) { var self = $(message); self.html(linkify(self.html())); }); $(".partner").on("mouseenter mouseleave", function() { $(this).find(".gray-scale, .colour").toggleClass("is-hidden"); }); }); Sign In Remember me Forgotten your password? Sign In Cancel Email or password not correct. Please try again Please wait... $(function(){ // Note: All the setup needs to run against a name attribute and *not* the id due the clonish // nature of facebox... $("a[id=googleSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("GOOGLE"); $("form[id=oAuthForm]").submit(); }); $("a[id=facebookSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("FACEBOOK"); $("form[id=oAuthForm]").submit(); }); $("a[id=orcidSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("ORCID"); $("form[id=oAuthForm]").submit(); }); }); If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password. The email address should be the one you originally registered with F1000. Email address not valid, please try again You registered with F1000 via Google, so we cannot reset your password. To sign in, please click here . If you still need help with your Google account password, please click here . You registered with F1000 via Facebook, so we cannot reset your password. To sign in, please click here . If you still need help with your Facebook account password, please click here . Code not correct, please try again Reset password Cancel Email us for further assistance. Server error, please try again. If your email address is registered with us, we will email you instructions to reset your password. If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance. Please wait... Register $(document).ready(function () { signIn.createSignInAsRow($("#sign-in-form-gfb-popup")); $(".target-field").each(function () { var uris = $(this).val().split("/"); if (uris.pop() === "login") { $(this).val(uris.toString().replace(",","/")); } }); });